

Association of PD-1, PD-1 Ligands, and Other Features of Microenvironment with Response to Anti-“PD-1 Therapies

Clinical Cancer Research

20, 5064-5074

DOI: 10.1158/1078-0432.ccr-13-3271

Citation Report

#	ARTICLE	IF	CITATIONS
1	Calcium-Induced Contraction of the Rhizoplast of a Quadriflagellate Green Alga. <i>Science</i> , 1978, 202, 975-977.	12.6	185
2	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. <i>Journal of Receptor, Ligand and Channel Research</i> , 2014, , 1.	0.7	2
3	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 357.	0.7	60
4	Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. <i>Oncolmmunology</i> , 2014, 3, e963413.	4.6	62
5	The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade. <i>Clinical Cancer Research</i> , 2014, 20, 4982-4984.	7.0	80
6	NKT Cell Networks in the Regulation of Tumor Immunity. <i>Frontiers in Immunology</i> , 2014, 5, 543.	4.8	110
7	Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. <i>Immunotherapy</i> , 2014, 6, 1017-1020.	2.0	10
8	Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2965-2970.	2.5	432
9	PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> , 2014, 515, 568-571.	27.8	5,429
10	Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 ⁺ PD-L1 ⁺ phenotype in prostate cancer. <i>Oncolmmunology</i> , 2014, 3, e955331.	4.6	59
11	Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e962401.	4.6	37
12	Novel immune checkpoint blocker approved for the treatment of advanced melanoma. <i>Oncolmmunology</i> , 2014, 3, e967147.	4.6	27
13	PD-L1 expression and tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2014, 3, e29288.	4.6	60
14	Tertiary lymphoid structures in cancer and beyond. <i>Trends in Immunology</i> , 2014, 35, 571-580.	6.8	418
15	Unvalidated antibodies and misleading results. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 457-458.	2.5	29
16	Immunotherapy for non-small-cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1061-1064.	3.1	5
17	Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 541-549.	1.2	171
18	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. <i>Journal of Thoracic Oncology</i> , 2015, 10, 985-989.	1.1	241

#	ARTICLE	IF	CITATIONS
20	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.5	2
21	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1726-1735.	1.1	208
22	Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 490-500.	3.3	134
23	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. <i>Cancer Science</i> , 2015, 106, 945-950.	3.9	78
24	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2015, 126, 2193-2201.	1.4	390
25	Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC). <i>Current Cancer Drug Targets</i> , 2015, 15, 243-255.	1.6	15
26	Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2015, 22, 109-120.	1.8	41
27	Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?. <i>Melanoma Management</i> , 2015, 2, 5-8.	0.5	0
29	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S23252.	1.3	27
30	Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. <i>Internal Medicine Journal</i> , 2015, 45, 696-701.	0.8	28
31	Cytotoxic T-cell Cytokines Put Cancer Under Arrest. <i>Cancer Immunology Research</i> , 2015, 3, 23-25.	3.4	1
32	Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. <i>Melanoma Research</i> , 2015, 25, 503-509.	1.2	59
33	T-cell checkpoint inhibitors in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2015, 25, 411-415.	1.8	7
34	Tumor-Infiltrating Lymphocyte Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 450-464.	2.0	45
35	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. <i>Oncotarget</i> , 2015, 6, 34221-34227.	1.8	198
36	Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 41228-41236.	1.8	163
37	Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 81.	0.7	10
38	Prognostic and predictive value of PDL1 expression in breast cancer. <i>Oncotarget</i> , 2015, 6, 5449-5464.	1.8	424

#	ARTICLE	IF	CITATIONS
39	Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer: Targets and Therapy, 2015, 6, 55.	2.7	10
40	PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPÎ± axis in HPV negative head and neck squamous cell carcinoma. Oncotarget, 2015, 6, 42067-42080.	1.8	95
41	Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy. ImmunoTargets and Therapy, 2015, 4, 55.	5.8	3
42	PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget, 2015, 6, 234-242.	1.8	227
43	Biomarkers of Response to Immune Modulatory Therapies in Cancer. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	1
44	New developments in the management of advanced melanoma – role of pembrolizumab. OncoTargets and Therapy, 2015, 8, 2535.	2.0	16
45	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 516.	4.8	79
46	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15048.	4.1	7
47	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget, 2015, 6, 4704-4716.	1.8	127
48	Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-Î®B. PLoS ONE, 2015, 10, e0123410.	2.5	181
49	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142.	2.5	390
50	Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. BioMed Research International, 2015, 2015, 1-8.	1.9	43
51	From mice to humans: developments in cancer immunoediting. Journal of Clinical Investigation, 2015, 125, 3338-3346.	8.2	271
52	<i>PDL1</i> expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, 2015, 6, 13506-13519.	1.8	105
53	New Insights in Cutaneous Melanoma Immune-Therapy â€” Tackling Immune-Suppression and Specific Anti-Tumoral Response. , 0, , .		2
54	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	27.0	7,696
55	Monoclonal antibodies specific to human Î”42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. MAbs, 2015, 7, 620-629.	5.2	6
57	Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opinion on Biological Therapy, 2015, 15, 1191-1203.	3.1	75

#	ARTICLE	IF	CITATIONS
58	PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology, 2015, 23, 32-38.	3.5	483
59	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics, 2015, 37, 764-782.	2.5	469
60	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E μ -TCL1 CLL mouse model. Blood, 2015, 126, 212-221.	1.4	111
61	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncology, 2015, 11, 133-140.	2.4	9
62	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. Cancer Research, 2015, 75, 2928-2936.	0.9	193
63	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunology Research, 2015, 3, 506-517.	3.4	262
64	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology, 2015, 11, 2175-2191.	2.4	5
65	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunology Research, 2015, 3, 855-863.	3.4	60
66	Checkpoint blockade in lymphoma. Hematology American Society of Hematology Education Program, 2015, 2015, 69-73.	2.5	11
67	Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role. European Journal of Cancer, 2015, 51, 2578-2579.	2.8	0
68	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315.	3.4	114
69	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. Cancer Drug Discovery and Development, 2015, , 99-127.	0.4	4
70	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804.	4.6	51
71	Prognostic and predictive immune gene signatures in breast cancer. Current Opinion in Oncology, 2015, 27, 433-444.	2.4	75
72	New hope on the horizon for patients with metastatic colorectal cancer. Colorectal Cancer, 2015, 4, 229-239.	0.8	0
73	Multifocal BRAFV600E-Mutated Melanoma in situ on the Foot. Case Reports in Dermatology, 2015, 7, 322-327.	0.8	0
74	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research, 2015, 3, 326-332.	3.4	310
75	Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncology, 2015, 51, 221-228.	1.5	256

#	ARTICLE	IF	CITATIONS
76	PD-L1 expression in small cell neuroendocrine carcinomas. European Journal of Cancer, 2015, 51, 421-426.	2.8	209
77	Immune Checkpoint Blockade in Patients With Melanoma Metastatic to the Brain. Seminars in Oncology, 2015, 42, 459-465.	2.2	20
78	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Current Opinion in Immunology, 2015, 33, 23-35.	5.5	298
79	Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinical Cancer Research, 2015, 21, 687-692.	7.0	801
80	Targeting PD1“PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia, 2015, 29, 1441-1444.	7.2	185
81	Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 2015, 33, 1974-1982.	1.6	2,220
82	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 12-21.	3.2	22
83	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 257-265.	10.7	1,269
84	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research, 2015, 21, 3031-3040.	7.0	355
85	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 2015, 14, 847-856.	4.1	1,787
86	New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. Current Opinion in Immunology, 2015, 33, 93-100.	5.5	33
87	The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 127-135.	2.8	51
88	Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents. Frontiers in Immunology, 2015, 6, 29.	4.8	139
89	Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncology, 2015, 11, 1307-1326.	2.4	158
90	Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 2015, 14, 561-584.	46.4	1,058
91	Update in Lung Cancer 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 283-294.	5.6	36
92	Immune Checkpoint Inhibition in Renal Cell Carcinoma. , 2015, , 259-279.		0
93	Immune Checkpoint Blockade in Malignant Mesothelioma. Seminars in Oncology, 2015, 42, 418-422.	2.2	8

#	ARTICLE	IF	CITATIONS
94	The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors. <i>Journal of Immunology</i> , 2015, 195, 1891-1901.	0.8	14
95	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. <i>Clinical Cancer Research</i> , 2015, 21, 3969-3976.	7.0	205
96	PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. <i>Cancer Immunology Research</i> , 2015, 3, 946-955.	3.4	66
97	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. <i>Immunotherapy</i> , 2015, 7, 499-512.	2.0	18
98	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>OncImmunology</i> , 2015, 4, e1008814.	4.6	102
99	Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. <i>Translational Research</i> , 2015, 166, 721-732.e1.	5.0	95
100	Association of Polymerase ϵ -Mutated and Microsatellite-Unstable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. <i>JAMA Oncology</i> , 2015, 1, 1319.	7.1	523
101	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	28.4	576
102	The immunocheckpoints in modern oncology: the next 15 years. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 917-921.	3.1	24
103	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	5.0	41
104	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. <i>Trends in Molecular Medicine</i> , 2015, 21, 482-491.	6.7	146
105	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. <i>Oncologist</i> , 2015, 20, 812-822.	3.7	198
106	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. <i>Molecular Therapy</i> , 2015, 23, 1630-1640.	8.2	165
107	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	2.2	259
108	Therapeutic Combinations of Immune-Modulating Antibodies in Melanoma and Beyond. <i>Seminars in Oncology</i> , 2015, 42, 488-494.	2.2	19
109	CTLA4 blockade in patients with malignant mesothelioma. <i>Lancet Respiratory Medicine</i> , 2015, 3, 261-263.	10.7	0
110	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. <i>Lung Cancer</i> , 2015, 88, 24-33.	2.0	187
111	STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. <i>Science Translational Medicine</i> , 2015, 7, 283ra52.	12.4	543

#	ARTICLE	IF	CITATIONS
112	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 2015, 372, 2006-2017.	27.0	2,489
113	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs, 2015, 75, 563-575.	10.9	18
114	Immune checkpoint blockade in hematologic malignancies. Blood, 2015, 125, 3393-3400.	1.4	208
115	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunology Research, 2015, 3, 399-411.	3.4	387
116	Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Research, 2015, 75, 2139-2145.	0.9	1,167
117	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€‘small cell lung cancer. Science, 2015, 348, 124-128.	12.6	6,756
118	<sc>PD</sc>â€‘L1 expression in melanoma shows marked heterogeneity within and between patients: implications for antiâ€‘<sc>PD</sc>â€‘L1/<sc>PD</sc>â€‘L</sc> clinical trials. Pigment Cell and Melanoma Research, 2015, 28, 245-253.	3.3	356
119	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clinical Lung Cancer, 2015, 16, e25-e35.	2.6	100
120	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research, 2015, 21, 3052-3060.	7.0	198
121	Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer, 2015, 88, 154-159.	2.0	153
122	Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2015, 27, 108-117.	2.4	26
123	Diffuse High Intensity PDâ€‘L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2015, 10, 500-508.	1.1	129
124	MicroRNA control of protein expression noise. Science, 2015, 348, 128-132.	12.6	337
125	Clinical deployment of antibodies for treatment of melanoma. Molecular Immunology, 2015, 67, 18-27.	2.2	11
126	Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies. Seminars in Oncology, 2015, 42, 448-458.	2.2	22
127	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 2015, 27, 450-461.	16.8	3,266
128	PD-L1 expression as a potential predictive biomarker. Lancet Oncology, The, 2015, 16, 1285-1287.	10.7	98
129	Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. Oncoimmunology, 2015, 4, e1026504.	4.6	25

#	ARTICLE	IF	CITATIONS
130	Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Review of Anticancer Therapy, 2015, 15, 1135-1141.	2.4	22
131	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. Cancer Biology and Therapy, 2021, 22, 513-526.	3.4	24
132	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. Cancer Immunology Research, 2015, 3, 110-115.	3.4	45
133	Predictors of clinical response to immunotherapy with or without radiotherapy. Journal of Radiation Oncology, 2015, 4, 339-345.	0.7	17
134	Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterology Report, 2015, 3, gov053.	1.3	80
135	Immunomodulation: checkpoint blockade etc.: Fig. 1.. Neuro-Oncology, 2015, 17, vii26-vii31.	1.2	26
136	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 2015, 36, 822-846.	8.7	242
137	Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Medicine, 2015, 13, 202.	5.5	177
138	Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer. Drugs, 2015, 75, 1925-1934.	10.9	23
139	Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocrine-Related Cancer, 2015, 22, R165-R182.	3.1	52
140	Nivolumab: A Review in Advanced Melanoma. Drugs, 2015, 75, 1413-1424.	10.9	44
141	Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology, 2015, 11, 504-514.	10.1	307
142	Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: Table 1.. Neuro-Oncology, 2015, 17, 1043-1045.	1.2	24
143	Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. European Journal of Cancer, 2015, 51, 2698-2707.	2.8	150
144	Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjugate Chemistry, 2015, 26, 2062-2069.	3.6	139
145	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology, the, 2015, 2, e445-e455.	4.6	74
146	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunology Research, 2015, 3, 1375-1385.	3.4	342
147	PDL1 expression is an independent prognostic factor in localized GIST. OncoImmunology, 2015, 4, e1002729.	4.6	75

#	ARTICLE	IF	CITATIONS
148	PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. <i>Oncolmunology</i> , 2015, 4, e1029701.	4.6	53
149	Immune checkpoint inhibitors in melanoma. <i>Melanoma Management</i> , 2015, 2, 267-284.	0.5	6
150	Immunopharmacogenomics. , 2015, , .		3
151	Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma. <i>Oncolmunology</i> , 2015, 4, e1029704.	4.6	26
152	Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic. <i>Oncolmunology</i> , 2015, 4, e1008858.	4.6	7
153	CD73: A potential biomarker for anti-PD-1 therapy. <i>Oncolmunology</i> , 2015, 4, e1046675.	4.6	33
154	Safety and Antitumor Activity of Anti-“PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4015-4022.	1.6	924
155	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 868-876.	7.7	358
156	CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 105-112.	4.2	18
157	Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. <i>Histopathology</i> , 2015, 66, 289-299.	2.9	99
158	Clinical blockade of PD1 and LAG3 – potential mechanisms of action. <i>Nature Reviews Immunology</i> , 2015, 15, 45-56.	22.7	524
159	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 311-319.	27.0	3,099
160	Five functional polymorphisms of B7/CD28 co-signaling molecules alter susceptibility to colorectal cancer. <i>Cellular Immunology</i> , 2015, 293, 41-48.	3.0	33
161	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075.	1.2	485
162	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	1.2	2,122
163	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. <i>Cancer Discovery</i> , 2015, 5, 43-51.	9.4	1,180
165	Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. <i>Oncotarget</i> , 2016, 7, 10557-10567.	1.8	154
166	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6075-6082.	2.0	47

#	ARTICLE	IF	CITATIONS
167	Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 32113-32128.	1.8	100
168	Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). <i>Oncotarget</i> , 2016, 7, 30323-30335.	1.8	297
169	Immune checkpoint inhibitors and prostate cancer: a new frontier?. <i>Oncology Reviews</i> , 2016, 10, 293.	1.8	47
170	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. <i>Cancer Biology and Medicine</i> , 2016, 13, 157-170.	3.0	86
171	Análise da expressão de PD-L1 no microambiente do câncer de pulmão de não pequenas células e de seu papel como potencial marcador preditivo. , 2016, 95, 76.	0.1	0
172	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. <i>JCI Insight</i> , 2016, 1, .	5.0	68
173	Immunological battlefield in gastric cancer and role of immunotherapies. <i>World Journal of Gastroenterology</i> , 2016, 22, 6373.	3.3	33
174	Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. <i>Oncotarget</i> , 2016, 7, 1707-1716.	1.8	25
175	Current State of Immune-Based Therapies for Glioblastoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e132-e139.	3.8	13
176	Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 649-650.	2.5	8
177	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e116-e122.	3.8	65
178	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 7.	0.9	3
179	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	1.8	100
180	PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN- γ and Can Be Expressed in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 581.	4.8	41
181	Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. <i>Frontiers in Immunology</i> , 2016, 7, 610.	4.8	111
182	Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405.		3
183	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. <i>International Journal of Molecular Sciences</i> , 2016, 17, 790.	4.1	32
184	PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1046.	4.1	20

#	ARTICLE	IF	CITATIONS
185	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS ONE, 2016, 11, e0153954.	2.5	73
186	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Design, Development and Therapy, 2016, Volume 10, 3153-3161.	4.3	29
187	The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials. OncoTargets and Therapy, 2016, Volume 9, 5867-5874.	2.0	22
188	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. Journal of Cancer, 2016, 7, 484-489.	2.5	106
189	High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF- κ B signaling pathway in non-small cell lung cancer cells. OncoTargets and Therapy, 2016, Volume 9, 6511-6518.	2.0	13
190	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget, 2016, 7, 74350-74361.	1.8	35
191	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget, 2016, 7, 10215-10227.	1.8	158
192	Checkpoint Inhibition. Cancer Journal (Sudbury, Mass), 2016, 22, 17-22.	2.0	17
193	RANKL expression is a useful marker for differentiation of pagetoid squamous cell carcinoma <i>in situ</i> from extramammary Paget disease. Journal of Cutaneous Pathology, 2016, 43, 772-775.	1.3	7
194	Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. American Journal of Surgical Pathology, 2016, 40, 443-453.	3.7	51
195	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer, 2016, 98, 51-58.	2.0	110
196	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321.	7.0	182
197	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Therapeutic Advances in Urology, 2016, 8, 319-326.	2.0	25
198	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. Cancer Treatment Reviews, 2016, 48, 61-68.	7.7	102
199	Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology, 2016, 5, e1204507.	4.6	107
200	Immunotherapy in colorectal cancer: What have we learned so far?. Clinica Chimica Acta, 2016, 460, 78-87.	1.1	12
201	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology, 2016, 5, e1207842.	4.6	29
202	Functional reprogramming of human prostate cancer to promote local attraction of effector CD8 ⁺ T cells. Prostate, 2016, 76, 1095-1105.	2.3	48

#	ARTICLE	IF	CITATIONS
203	The evolving role of immunotherapy in prostate cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 232-240.	2.4	10
204	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 626-639.	2.8	80
205	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. <i>Histopathology</i> , 2016, 68, 1079-1089.	2.9	135
206	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. <i>ESMO Open</i> , 2016, 1, e000122.	4.5	55
207	Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 915-922.	4.9	94
208	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I pre-analytical and analytical validation. , 2016, 4, 76.		155
209	The role of immune checkpoint inhibition in the treatment of ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 11.	3.6	118
210	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. <i>Cell</i> , 2016, 167, 1540-1554.e12.	28.9	830
211	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e542-e551.	10.7	1,274
212	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016, 17, 218.	8.8	1,980
215	TCR diversity a universal cancer immunotherapy biomarker?. , 2016, 4, 69.		18
216	Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. , 2016, 4, 71.		12
217	Biochemistry of Oxidative Stress. , 2016, , .		5
218	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
220	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, 16025.	17.1	35
221	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2016, 2, 16002.	5.2	31
222	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. <i>Journal of Translational Medicine</i> , 2016, 14, 173.	4.4	103
223	Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1496-1506.	3.7	134

#	ARTICLE	IF	CITATIONS
224	The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. <i>Oncolimmunology</i> , 2016, 5, e1247135.	4.6	165
225	Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2610-2617.	1.5	128
226	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. <i>European Journal of Cancer</i> , 2016, 59, 160-170.	2.8	78
227	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. <i>Oncolimmunology</i> , 2016, 5, e1134412.	4.6	135
228	Disentangling the relationship between tumor genetic programs and immune responsiveness. <i>Current Opinion in Immunology</i> , 2016, 39, 150-158.	5.5	57
229	Immune checkpoint inhibitors in lung cancer: past, present and future. <i>Future Oncology</i> , 2016, 12, 1151-1163.	2.4	26
230	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. <i>Oncolimmunology</i> , 2016, 5, e1165377.	4.6	42
231	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. <i>European Journal of Cancer</i> , 2016, 62, 36-45.	2.8	105
232	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 47.	17.0	271
233	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. <i>Annals of Medicine</i> , 2016, 48, 428-439.	3.8	32
234	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <i>Drugs</i> , 2016, 76, 925-945.	10.9	123
235	PDL1: The Illusion of an Ideal Biomarker. <i>European Urology Focus</i> , 2016, 1, 269-271.	3.1	11
236	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 31.	3.0	57
237	PD-L1 Expression in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 964-975.	1.1	329
238	Investigational new drugs for brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 937-956.	4.1	16
239	Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2016, 76, 969-978.	10.9	34
240	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016, 130, 251-277.	2.2	107
241	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	7.0	480

#	ARTICLE	IF	CITATIONS
242	Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Human Pathology, 2016, 54, 157-164.	2.0	81
243	PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Modern Pathology, 2016, 29, 1104-1112.	5.5	210
244	Oncolytic virotherapy for urological cancers. Nature Reviews Urology, 2016, 13, 334-352.	3.8	18
245	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. Cancer Immunology Research, 2016, 4, 582-591.	3.4	35
246	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy, 2016, 8, 733-746.	2.0	28
247	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology, 2016, 37, 462-476.	6.8	232
248	Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling. Cell, 2016, 165, 272-275.	28.9	224
249	Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology, 2016, 5, e1052212.	4.6	83
250	PD-1 Blockade Boosts Radiofrequency Ablation-Induced Adaptive Immune Responses against Tumor. Clinical Cancer Research, 2016, 22, 1173-1184.	7.0	207
251	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287.	28.4	2,133
252	Advances in immunotherapy for melanoma. BMC Medicine, 2016, 14, 20.	5.5	111
253	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 α and STAT3. Oncoimmunology, 2016, 5, e1108514.	4.6	124
254	High co-expression of PD-L1 and HIF-1 α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. European Journal of Cancer, 2016, 60, 125-135.	2.8	91
255	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Human Vaccines and Immunotherapeutics, 2016, 12, 2219-2231.	3.3	49
256	Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2016, 10, 781-798.	2.5	29
257	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. International Immunology, 2016, 28, 373-382.	4.0	143
259	Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. Clinical Cancer Research, 2016, 22, 4727-4734.	7.0	74
260	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. Medical Oncology, 2016, 33, 59.	2.5	22

#	ARTICLE	IF	CITATIONS
261	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <i>OncolImmunology</i> , 2016, 5, e1131379.	4.6	94
262	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. <i>Cancer Research</i> , 2016, 76, 3496-3506.	0.9	33
263	Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2863-2873.	3.6	137
264	PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. <i>Blood</i> , 2016, 128, 1374-1381.	1.4	112
265	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 845-857.	3.4	110
266	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48.		178
267	Critical parameters in targeted drug development: the pharmacological audit trail. <i>Seminars in Oncology</i> , 2016, 43, 436-445.	2.2	64
268	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. <i>Asian Journal of Urology</i> , 2016, 3, 195-202.	1.2	12
269	Biomarkers in Melanoma: Lessons from Translational Medicine. <i>Trends in Cancer</i> , 2016, 2, 305-312.	7.4	11
270	Molecular mechanisms of <sc>HLA</sc> class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. <i>Hla</i> , 2016, 88, 213-220.	0.6	43
271	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. <i>OncolImmunology</i> , 2016, 5, e1235107.	4.6	104
272	Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1511-1522.	4.2	17
273	Killer immunoglobulin-like receptor (KIR) and KIR ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1523-1532.	4.2	5
274	Targeting Immune Checkpoints in Hematologic Malignancies. <i>Pharmacological Reviews</i> , 2016, 68, 1014-1025.	16.0	36
275	The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. <i>Clinical Colorectal Cancer</i> , 2016, 15, 285-291.	2.3	73
276	Checkpoint Immunotherapy: Picking a Winner. <i>Cancer Discovery</i> , 2016, 6, 818-820.	9.4	8
277	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 79-87.	2.0	108
278	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <i>Investigational New Drugs</i> , 2016, 34, 677-684.	2.6	30

#	ARTICLE	IF	CITATIONS
279	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 910-921.	3.7	58
280	Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells. <i>Cancer Research</i> , 2016, 76, 3756-3766.	0.9	31
282	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2567-2578.	2.8	56
283	Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1461-1464.	1.5	71
284	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. <i>Cancer Medicine</i> , 2016, 5, 1481-1491.	2.8	86
285	PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. <i>Pharmacotherapy</i> , 2016, 36, 317-334.	2.6	82
286	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. <i>Cancer Science</i> , 2016, 107, 107-115.	3.9	28
287	Multi-class single-label classification of histopathological whole-slide images. , 2016, , .		2
288	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2016, 4, 726-733.	3.4	133
289	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet, The</i> , 2016, 388, 1002-1011.	13.7	132
290	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1255-1261.	3.3	12
291	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. <i>Modern Pathology</i> , 2016, 29, 1552-1564.	5.5	25
292	Molecular Evaluation of Colorectal Adenocarcinoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 427-439.	1.7	16
293	Immunotherapy in Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 203-223.	0.5	8
295	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. <i>Oncologist</i> , 2016, 21, 1200-1211.	3.7	211
296	PD-L1 in melanoma: facts and myths. <i>Melanoma Management</i> , 2016, 3, 187-194.	0.5	11
297	Advances in immunotherapy for melanoma management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2501-2511.	3.3	15
298	PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. <i>Human Pathology</i> , 2016, 58, 7-14.	2.0	135

#	ARTICLE	IF	CITATIONS
299	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	2.9	107
300	Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. <i>British Journal of Cancer</i> , 2016, 115, 490-496.	6.4	88
301	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	5.5	144
302	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1209-1223.	3.1	18
303	Immunotherapy for prostate cancer: the next step?. <i>Trends in Urology & Men's Health</i> , 2016, 7, 28-32.	0.4	1
304	Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. <i>ESMO Open</i> , 2016, 1, e000013.	4.5	36
305	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016, 4, 1038-1048.	3.4	62
306	BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. <i>Immunotherapy</i> , 2016, 8, 1351-1353.	2.0	6
307	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7769-E7777.	7.1	145
308	Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 1061-1071.	3.4	114
309	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. <i>Science Translational Medicine</i> , 2016, 8, 328rv4.	12.4	1,844
310	Nivolumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1247-1261.	2.4	20
313	Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies. <i>Clinical Journal of Oncology Nursing</i> , 2016, 20, 319-326.	0.6	3
314	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34540.	1.3	121
315	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
316	Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma. <i>Medicine (United States)</i> , 2016, 95, e5077.	1.0	1
317	Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. <i>Head and Neck</i> , 2016, 38, 1176-1186.	2.0	17
318	Interferon- γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 650-657.	3.4	22

#	ARTICLE	IF	CITATIONS
319	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	1.6	6
320	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1954-1961.	6.4	122
321	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Current Treatment Options in Oncology, 2016, 17, 40.	3.0	34
322	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 2016, 4, 679-687.	3.4	81
323	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Medical Oncology, 2016, 33, 80.	2.5	32
324	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 2016, 44, 1255-1269.	14.3	797
325	Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. Expert Review of Clinical Immunology, 2016, 12, 1347-1357.	3.0	24
327	Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. Current Treatment Options in Oncology, 2016, 17, 41.	3.0	33
328	Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials, 2016, 102, 187-197.	11.4	208
329	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. Journal of Thoracic Oncology, 2016, 11, 1819-1836.	1.1	31
330	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Seminars in Oncology, 2016, 43, 501-513.	2.2	10
331	Genomic and Epigenomic Alterations in Cancer. American Journal of Pathology, 2016, 186, 1724-1735.	3.8	130
332	Challenges & Perspectives of Immunotherapy Biomarkers & The HistoOncoImmuneâ„¢ Methodology. Expert Review of Precision Medicine and Drug Development, 2016, 1, 9-24.	0.7	5
333	Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. Diagnostic Pathology, 2016, 11, 44.	2.0	64
334	Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care, 2016, 11, 108-115.	1.4	45
335	Genomic determinants of cancer immunotherapy. Current Opinion in Immunology, 2016, 41, 32-38.	5.5	27
336	Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer, 2016, 99, 4-10.	2.0	81
337	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 1217.	7.1	216

#	ARTICLE	IF	CITATIONS
338	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785
339	Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. <i>Oncolmunology</i> , 2016, 5, e1153208.	4.6	36
340	Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. <i>Histopathology</i> , 2016, 69, 25-34.	2.9	177
341	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
342	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016, 12, 551-564.	2.4	8
343	Acquired resistance to immunotherapy and future challenges. <i>Nature Reviews Cancer</i> , 2016, 16, 121-126.	28.4	353
344	Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 183-187.	1.9	42
345	Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. <i>Cancer Research</i> , 2016, 76, 1381-1390.	0.9	451
346	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. <i>Pathology</i> , 2016, 48, 177-187.	0.6	210
347	Essential role of HDAC6 in the regulation of PD-L1 in melanoma. <i>Molecular Oncology</i> , 2016, 10, 735-750.	4.6	125
348	Cancer immune contexture and immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 39, 7-13.	5.5	132
349	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 46.	7.1	693
350	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. <i>Human Pathology</i> , 2016, 47, 52-63.	2.0	284
351	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 231-250.	0.5	36
352	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <i>Oncolmunology</i> , 2016, 5, e1100789.	4.6	45
353	CTLA-4 and PD-1 Pathways. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 98-106.	1.3	1,644
354	Cancer Immunosurveillance Caught in the Act. <i>Immunity</i> , 2016, 44, 525-526.	14.3	6
355	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3915-3923.	7.0	91

#	ARTICLE	IF	CITATIONS
356	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 4057-4066.	7.0	433
357	PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 293-302.	1.4	261
358	Immunotherapy for head and neck cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 168-175.	3.2	18
359	Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1393-1404.	2.8	28
360	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. <i>Onc Immunology</i> , 2016, 5, e1091146.	4.6	66
361	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	2.2	160
362	High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. <i>Familial Cancer</i> , 2016, 15, 405-412.	1.9	105
363	PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 88-98.	4.4	316
364	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.9	451
365	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674.	3.1	21
366	Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. <i>Cancer Immunology Research</i> , 2016, 4, 345-353.	3.4	214
367	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016, 7, 10501.	12.8	1,163
368	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	7.0	353
369	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2016, 22, 2261-2270.	7.0	217
370	Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 314-318.e5.	2.9	17
371	Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. <i>Human Pathology</i> , 2016, 52, 9-18.	2.0	80
372	Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 104-116.	3.3	9
373	Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 673-679.	3.0	6

#	ARTICLE	IF	CITATIONS
374	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 57, 91-103.	2.8	120
375	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 511-525.	2.8	212
376	High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 813-819.	4.2	53
377	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	21.8	718
379	Immunotherapy of Cancer. , 2016, , .		3
380	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-“PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	1.1	48
381	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 75-85.	4.4	105
382	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
383	Genetic and Epigenetic Regulation of PD-1 Expression. <i>Journal of Immunology</i> , 2016, 196, 2431-2437.	0.8	181
384	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. <i>Oncimmunology</i> , 2016, 5, e1064578.	4.6	91
385	Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCEVH Working Group. <i>Annals of Oncology</i> , 2016, 27, 397-408.	1.2	37
386	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. <i>Clinical Cancer Research</i> , 2016, 22, 2102-2104.	7.0	31
387	PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. <i>Cancer Biology and Therapy</i> , 2016, 17, 407-413.	3.4	113
388	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202.	0.6	19
389	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-“PD-1 Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 474-480.	3.4	17
390	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN γ That Induce PD-L1 Expression in Head and Neck Cancer. <i>Cancer Research</i> , 2016, 76, 1031-1043.	0.9	265
391	The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 91-99.	4.4	87
392	Current progress in immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 244-251.	7.2	149

#	ARTICLE	IF	CITATIONS
393	Novel Diagnostic and Therapeutic Strategies in the Management of Patients with Cancers of Unknown Primary Site. , 2016, , 173-190.		1
394	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 2016, 11, 345-351.	3.6	56
395	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology, 2016, 28, 64-72.	5.6	52
396	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatric Research, 2016, 79, 371-377.	2.3	12
397	PD-1 expression conditions T cell avidity within an antigen-specific repertoire. OncoImmunology, 2016, 5, e1104448.	4.6	47
398	Safety and efficacy of targeted agents monotherapy in advanced NSCLC. Expert Review of Clinical Pharmacology, 2016, 9, 143-155.	3.1	1
399	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. OncoImmunology, 2016, 5, e1057388.	4.6	239
400	Novel avenues in immunotherapies for colorectal cancer. Expert Review of Gastroenterology and Hepatology, 2016, 10, 465-480.	3.0	9
401	Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. Pathology and Oncology Research, 2016, 22, 331-339.	1.9	13
402	Combination cancer immunotherapies tailored to the tumour microenvironment. Nature Reviews Clinical Oncology, 2016, 13, 143-158.	27.6	753
403	The role of microenvironment and immunity in drug response in leukemia. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 414-426.	4.1	62
404	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 704-713.	7.0	173
405	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clinical Cancer Research, 2016, 22, 582-595.	7.0	88
406	Cancer Neoantigens and Applications for Immunotherapy. Clinical Cancer Research, 2016, 22, 807-812.	7.0	188
407	Novel immunotherapies in lymphoid malignancies. Nature Reviews Clinical Oncology, 2016, 13, 25-40.	27.6	224
408	Immunotherapy and tumor microenvironment. Cancer Letters, 2016, 370, 85-90.	7.2	242
409	Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Annals of Oncology, 2016, 27, 147-153.	1.2	466
410	PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 2016, 18, 195-205.	1.2	463

#	ARTICLE	IF	CITATIONS
411	The Immunotherapy Roadmap. <i>Clinical Cancer Research</i> , 2016, 22, 275-276.	7.0	2
412	Cancer of Unknown Primary. , 2016, , .		7
413	Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. <i>Gastric Cancer</i> , 2016, 19, 466-471.	5.3	124
414	Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. <i>Gut</i> , 2017, 66, 794-801.	12.1	377
415	Immune regulation of canine tumour and macrophage PD-L1 expression. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 534-549.	1.8	56
416	Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 61-67.	1.1	18
417	Elements of cancer immunity and the cancer's immune set point. <i>Nature</i> , 2017, 541, 321-330.	27.8	3,558
418	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. <i>Gut</i> , 2017, 66, 1463-1473.	12.1	173
419	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. <i>Journal of Cancer Research and Practice</i> , 2017, 4, 72-75.	0.2	1
420	Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 41-54.	4.4	74
421	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. <i>Modern Pathology</i> , 2017, 30, 530-538.	5.5	92
422	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. <i>Current Medical Research and Opinion</i> , 2017, 33, 749-759.	1.9	65
423	Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. <i>Gynecologic Oncology</i> , 2017, 144, 607-612.	1.4	61
424	Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 105, 17-22.	2.0	48
425	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now287.	1.2	128
426	<scp>PD</scp>-1 expression by canine T cells and functional effects of <scp>PD</scp>-1 blockade. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 1487-1502.	1.8	51
428	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. <i>Nature Communications</i> , 2017, 8, 14572.	12.8	279
429	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 387-394.	2.4	128

#	ARTICLE	IF	CITATIONS
430	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <i>Oncolmunology</i> , 2017, 6, e1286437.	4.6	28
431	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	7.0	117
432	The biology of uveal melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 109-140.	5.9	160
433	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	28.4	724
434	Potential immunotherapy targets in recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2017, 145, 462-468.	1.4	19
435	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3168-3180.	7.0	67
436	Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. <i>Oncolmunology</i> , 2017, 6, e1261241.	4.6	67
437	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. <i>Revue De Medecine Interne</i> , 2017, 38, 513-525.	1.0	36
439	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4416-4428.	7.0	252
440	Immune Microenvironment in Microsatellite-Unstable Endometrial Cancers: Hereditary or Sporadic Origin Matters. <i>Clinical Cancer Research</i> , 2017, 23, 4473-4481.	7.0	96
441	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. <i>Oncolmunology</i> , 2017, 6, e1299303.	4.6	20
442	Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. <i>Modern Pathology</i> , 2017, 30, 826-833.	5.5	101
443	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2017, 92, 283-290.	1.9	36
444	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. <i>Oncolmunology</i> , 2017, 6, e1278100.	4.6	65
445	A comprehensive review of immunotherapies in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 292-303.	4.4	55
446	Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. <i>Journal of Clinical Pathology</i> , 2017, 70, 255-259.	2.0	97
447	Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. <i>Human Pathology</i> , 2017, 64, 7-12.	2.0	64
448	High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. <i>Oncolmunology</i> , 2017, 6, e1284719.	4.6	64

#	ARTICLE	IF	CITATIONS
449	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. <i>Cell</i> , 2017, 168, 707-723.	28.9	3,483
450	Checkpoint Blockade in Lung Cancer and Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 274-282.	5.6	59
451	Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. <i>JAMA Dermatology</i> , 2017, 153, 285.	4.1	39
452	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. <i>Molecular Imaging and Biology</i> , 2017, 19, 903-914.	2.6	91
453	The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 850-859.	1.1	83
454	Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. <i>Immunological Reviews</i> , 2017, 276, 9-25.	6.0	13
455	Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. <i>Oncolimmunology</i> , 2017, 6, e1284720.	4.6	18
456	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 41-54.	6.4	55
457	Targeting the immune system in glioblastoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 121-131.	0.7	0
458	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. <i>Clinical Cancer Research</i> , 2017, 23, 4938-4944.	7.0	120
459	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. <i>Journal of Controlled Release</i> , 2017, 256, 26-45.	9.9	41
460	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. <i>Protein and Cell</i> , 2017, 8, 573-589.	11.0	67
461	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	3.4	400
462	Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation. <i>Journal of Immunotherapy</i> , 2017, 40, 155-163.	2.4	5
463	Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>Oncology Research and Treatment</i> , 2017, 40, 7-13.	1.2	9
464	Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. <i>Annals of Diagnostic Pathology</i> , 2017, 29, 17-22.	1.3	29
465	Epigenetics and immunotherapy: The current state of play. <i>Molecular Immunology</i> , 2017, 87, 227-239.	2.2	167
466	PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. <i>Oncolimmunology</i> , 2017, 6, e1327494.	4.6	52

#	ARTICLE	IF	CITATIONS
467	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5024-5033.	7.0	192
468	TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. <i>Tumor Biology</i> , 2017, 39, 101042831769835.	1.8	13
469	Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study. <i>Clinical Lung Cancer</i> , 2017, 18, 631-639.e2.	2.6	31
470	Immunotherapy in advanced melanoma: a network meta-analysis. <i>Immunotherapy</i> , 2017, 9, 471-479.	2.0	9
471	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	4.1	170
472	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4993-4998.	7.1	614
473	The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2017, 96, e6398.	1.0	43
474	PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages. <i>American Journal of Surgical Pathology</i> , 2017, 41, 334-342.	3.7	143
475	PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. <i>American Journal of Surgical Pathology</i> , 2017, 41, 326-333.	3.7	113
476	Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1886-1890.	7.0	189
477	Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. <i>International Journal of Cancer</i> , 2017, 140, 1396-1404.	5.1	48
478	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3158-3167.	7.0	426
479	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1977-1984.	2.5	14
480	PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.	6.3	43
481	Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1560-1566.	5.0	73
482	Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219.	2.8	7
483	Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. <i>Journal of Surgical Oncology</i> , 2017, 116, 55-62.	1.7	46
484	Recent progress in immunotherapy for urological cancer. <i>International Journal of Urology</i> , 2017, 24, 735-742.	1.0	12

#	ARTICLE	IF	CITATIONS
485	Evolving adoptive cellular therapies in urological malignancies. <i>Lancet Oncology</i> , The, 2017, 18, e341-e353.	10.7	22
486	Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. <i>Oncolimmunology</i> , 2017, 6, e1312240.	4.6	68
487	Correlation of immune phenotype with IDH mutation in diffuse glioma. <i>Neuro-Oncology</i> , 2017, 19, 1460-1468.	1.2	213
488	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	12.6	4,945
489	In Vivo Imaging of the Programmed Death Ligand 1 by ¹⁸ F PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1852-1857.	5.0	84
490	Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2017, 10, 511-517.	3.7	47
491	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. <i>Oncolimmunology</i> , 2017, 6, e1313371.	4.6	11
492	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 431-439.	3.2	73
493	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <i>BMC Medicine</i> , 2017, 15, 55.	5.5	65
494	PD-L1 expression in neuroendocrine tumors of the lung. <i>Lung Cancer</i> , 2017, 108, 115-120.	2.0	98
495	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017, 116, 1141-1147.	6.4	112
496	Strategies for Increasing Pancreatic Tumor Immunogenicity. <i>Clinical Cancer Research</i> , 2017, 23, 1656-1669.	7.0	131
497	Biomarkers to predict prognosis and response to checkpoint inhibitors. <i>International Journal of Clinical Oncology</i> , 2017, 22, 629-634.	2.2	57
498	Immune modulator-induced changes in the gastrointestinal tract. <i>Histopathology</i> , 2017, 71, 494-496.	2.9	56
499	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. <i>Medical Oncology</i> , 2017, 34, 71.	2.5	17
500	Molecular genetic and immunotherapeutic targets in metastatic melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 281-293.	2.8	16
502	Biomarkers and Immunotherapeutic Targets in Glioblastoma. <i>World Neurosurgery</i> , 2017, 102, 494-506.	1.3	29
503	Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 49-56.	1.0	3

#	ARTICLE	IF	CITATIONS
504	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. Expert Opinion on Biological Therapy, 2017, 17, 735-746.	3.1	66
505	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomarker Research, 2017, 5, 12.	6.8	149
506	Immuno-Oncology: The Third Paradigm in Early Drug Development. Targeted Oncology, 2017, 12, 125-138.	3.6	22
507	Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. Cancer Immunology Research, 2017, 5, 118-126.	3.4	56
508	PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Research and Treatment, 2017, 162, 19-30.	2.5	86
509	PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e319-e321.	2.4	4
510	Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Immunobiology, 2017, 222, 651-657.	1.9	51
511	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology, 2017, 6, e1264565.	4.6	102
512	Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. American Journal of Pathology, 2017, 187, 304-317.	3.8	22
513	Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers in Medicine, 2017, 11, 53-67.	1.4	11
514	PD-1 and PDL-1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD-1 predicts poor survival. Hematological Oncology, 2017, 35, 487-496.	1.7	47
515	Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. International Journal of Oncology, 2017, 50, 41-48.	3.3	65
516	Role of FcγR interactions in the antitumor activity of therapeutic antibodies. Immunology and Cell Biology, 2017, 95, 340-346.	2.3	35
517	Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case report. CNS Oncology, 2017, 6, 275-280.	3.0	14
518	Integration of nano drug-delivery system with cancer immunotherapy. Therapeutic Delivery, 2017, 8, 987-1000.	2.2	34
519	Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. British Journal of Cancer, 2017, 117, 1753-1760.	6.4	40
520	A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. Future Science OA, 2017, 3, FSO244.	1.9	24
521	Cancer Evolution during Immunotherapy. Cell, 2017, 171, 740-742.	28.9	28

#	ARTICLE	IF	CITATIONS
522	Immune checkpoint inhibitors in renal cell carcinoma. <i>Clinical Science</i> , 2017, 131, 2627-2642.	4.3	62
523	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. <i>Cancer Research</i> , 2017, 77, 6365-6374.	0.9	77
524	Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy. <i>Cellular Immunology</i> , 2017, 320, 38-45.	3.0	10
525	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. <i>Cancer Cytopathology</i> , 2017, 125, 896-907.	2.4	164
526	Danger signals: Chemotherapy enhancers?. <i>Immunological Reviews</i> , 2017, 280, 175-193.	6.0	50
527	Immunomodulation by ionizing radiation—impact for design of radioimmunotherapies and for treatment of inflammatory diseases. <i>Immunological Reviews</i> , 2017, 280, 231-248.	6.0	140
528	Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. <i>Journal of Immunotherapy</i> , 2017, 40, 323-333.	2.4	68
529	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 1046-1055.	3.4	42
530	Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. <i>Human Pathology</i> , 2017, 70, 49-54.	2.0	38
531	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. <i>American Journal of Clinical Pathology</i> , 2017, 148, 441-449.	0.7	19
532	Circulating tumour cell PD-L1 test for head and neck cancers. <i>Oral Oncology</i> , 2017, 75, 6-7.	1.5	15
533	Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. <i>Cancer</i> , 2017, 123, 4823-4831.	4.1	79
534	Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. <i>Cell Death and Disease</i> , 2017, 8, e3004-e3004.	6.3	90
535	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017, 84, 212-218.	2.8	132
536	Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?. <i>American Journal of Clinical Pathology</i> , 2017, 148, 208-214.	0.7	26
537	PD-1/PD-L1 and immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2017, 407, 57-65.	7.2	235
538	Immunotherapy for metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 566-571.	1.8	18
539	Optimizing tumor immune response through combination of radiation and immunotherapy. <i>Medical Oncology</i> , 2017, 34, 165.	2.5	14

#	ARTICLE	IF	CITATIONS
540	Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. Journal of Digestive Diseases, 2017, 18, 574-581.	1.5	70
541	Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. Cancer Immunology Research, 2017, 5, 871-884.	3.4	63
542	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Scientific Reports, 2017, 7, 11671.	3.3	57
543	Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. Endocrine-Related Cancer, 2017, 24, T261-T281.	3.1	33
544	Novel Immunologic Approaches to Melanoma Treatment. Actas Dermo-sifiliográficas, 2017, 108, 708-720.	0.4	0
545	Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clinical Cancer Research, 2017, 23, 6812-6822.	7.0	77
546	A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. Journal of the Royal Society Interface, 2017, 14, 20170320.	3.4	118
547	Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. Hormone Molecular Biology and Clinical Investigation, 2017, 32, .	0.7	15
548	The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clinical Cancer Research, 2017, 23, 4970-4979.	7.0	76
549	Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. Surgical Oncology, 2017, 26, 423-430.	1.6	20
550	Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. OncoImmunology, 2017, 6, e1356153.	4.6	89
551	Tumor Dormancy and Recurrence. Cancer Drug Discovery and Development, 2017, , .	0.4	2
552	Immunotherapy in genitourinary cancers: where are we going?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 73-78.	0.7	2
553	PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes. International Journal of Gynecological Cancer, 2017, 27, 554-561.	2.5	66
554	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Laboratory Investigation, 2017, 97, 1063-1071.	3.7	156
555	Theranostic Gold Nanoantennas for Simultaneous Multiplexed Raman Imaging of Immunomarkers and Photothermal Therapy. ACS Omega, 2017, 2, 3583-3594.	3.5	29
556	Novedades en inmunología del melanoma. Actas Dermo-sifiliográficas, 2017, 108, 708-720.	0.4	6
557	A novel bifunctional anti-PD-L1/TGF- β 2 Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. OncoImmunology, 2017, 6, e1349589.	4.6	137

#	ARTICLE	IF	CITATIONS
558	Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC—a computational study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 157-164.	0.4	8
559	Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology. <i>Methods</i> , 2017, 130, 23-35.	3.8	28
560	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. <i>Modern Pathology</i> , 2017, 30, 1622-1632.	5.5	62
561	Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification. <i>Modern Pathology</i> , 2017, 30, 1516-1526.	5.5	22
562	Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way. <i>Pharmacogenomics</i> , 2017, 18, 1299-1304.	1.3	4
563	How to Escape the Immune Response. <i>Transplantation</i> , 2017, 101, 2825-2829.	1.0	1
564	PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer. <i>Cancer Letters</i> , 2017, 406, 27-35.	7.2	31
565	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2310-2325.	6.4	46
566	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	4.0	106
567	Ensemble Modeling Approach Targeting Heterogeneous RNA-Seq data: Application to Melanoma Pseudogenes. <i>Scientific Reports</i> , 2017, 7, 17344.	3.3	2
568	Checkpoint inhibition in pediatric hematologic malignancies. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 379-394.	0.8	23
569	Personalised medicine for nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2017, 26, 170066.	7.1	37
570	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 694-700.	1.6	36
571	Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. <i>Immunotherapy</i> , 2017, 9, 695-699.	2.0	0
572	The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 38-57.	4.4	99
573	First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. <i>Oncolimmunology</i> , 2017, 6, e1338235.	4.6	52
574	Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using <i>Escherichia coli</i> host cell machinery. <i>Immunology Letters</i> , 2017, 190, 34-41.	2.5	9
575	Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. <i>Oral Oncology</i> , 2017, 71, 87-94.	1.5	26

#	ARTICLE	IF	CITATIONS
576	Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5948-5958.	7.0	85
577	Checkpoint inhibition for advanced mucosal melanoma. <i>European Journal of Dermatology</i> , 2017, 27, 160-165.	0.6	17
579	PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. <i>Pathology</i> , 2017, 49, 499-505.	0.6	39
580	Glancing at the complex biology of T-cells through the microenvironment of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1019-1021.	1.3	1
581	PD-1/PD-L1 immune-checkpoint blockade in B-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 203-220.	27.6	358
582	Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. <i>Head and Neck Pathology</i> , 2017, 11, 203-211.	2.6	23
583	Gene-expression profiling to predict responsiveness to immunotherapy. <i>Cancer Gene Therapy</i> , 2017, 24, 134-140.	4.6	72
584	Basis for molecular diagnostics and immunotherapy for esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 33-45.	2.4	23
585	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <i>Annals of Oncology</i> , 2017, 28, 57-74.	1.2	45
586	Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 469-481.	11.4	58
587	Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. <i>International Journal of Cancer</i> , 2017, 140, 948-958.	5.1	42
588	PD-1 inhibitor gastroenterocolitis: case series and appraisal of immunomodulatory gastroenterocolitis™. <i>Histopathology</i> , 2017, 70, 558-567.	2.9	198
589	Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 135-149.	3.1	5
590	A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. <i>JAMA Oncology</i> , 2017, 3, 256.	7.1	164
591	Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. <i>Clinical Cancer Research</i> , 2017, 23, 149-158.	7.0	77
592	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. <i>European Urology</i> , 2017, 71, 237-246.	1.9	62
593	An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 85-93.	3.8	28
594	Advances in immunotherapy for the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 1-9.	2.9	65

#	ARTICLE	IF	CITATIONS
595	Assessing PDL-1 and PD-1 in Nonâ€“Small Cell Lung Cancer: A Novel Immunoscore Approach. Clinical Lung Cancer, 2017, 18, 220-233.e8.	2.6	72
596	Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma. Translational Oncology, 2017, 10, 10-16.	3.7	64
597	Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 1220-1226.	7.0	92
598	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. Journal of Investigative Dermatology, 2017, 137, 484-493.	0.7	29
599	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 110-120.	1.1	108
600	Stromal and intraepithelial tumorâ€“infiltrating lymphocytes in colorectal carcinoma. Oncology Letters, 2017, 14, 6421-6432.	1.8	27
601	Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Molecular and Clinical Oncology, 2017, 8, 310-314.	1.0	22
602	Tumor Immuno-Environment in Cancer Progression and Therapy. Advances in Experimental Medicine and Biology, 2017, 1036, 1-18.	1.6	31
603	Water-soluble polyacetylene: a promising tool for sustainable drug delivery?. Therapeutic Delivery, 2017, 8, 929-932.	2.2	1
604	Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?. Hematology American Society of Hematology Education Program, 2017, 2017, 284-294.	2.5	22
605	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma. JCO Precision Oncology, 2017, 1, 1-12.	3.0	8
606	PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget, 2017, 8, 53978-53988.	1.8	32
607	Updated Landscape of the Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine. , 2017, , .		0
608	Th17 immune microenvironment in Epstein-Barr virusâ€“negative Hodgkin lymphoma: implications for immunotherapy. Blood Advances, 2017, 1, 1324-1334.	5.2	36
609	Immune Checkpoint in Glioblastoma: Promising and Challenging. Frontiers in Pharmacology, 2017, 8, 242.	3.5	133
610	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets and Therapy, 2017, Volume 10, 2349-2363.	2.0	35
611	Prediction of Anti-cancer Nanotherapy Efficacy by Imaging. Nanotheranostics, 2017, 1, 296-312.	5.2	64
612	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Medical Sciences (Basel, Switzerland), 2017, 5, 28.	2.9	22

#	ARTICLE	IF	CITATIONS
613	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <i>Theranostics</i> , 2017, 7, 3585-3594.	10.0	214
614	PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. <i>BioMed Research International</i> , 2017, 2017, 1-8.	1.9	13
615	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 85.	4.1	25
616	Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 83.	4.8	38
617	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <i>Frontiers in Immunology</i> , 2017, 8, 961.	4.8	93
618	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Oncology</i> , 2017, 7, 233.	2.8	61
619	Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. <i>BioMed Research International</i> , 2017, 2017, 1-13.	1.9	22
620	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. <i>BioMed Research International</i> , 2017, 2017, 1-7.	1.9	65
621	Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 191-197.	2.2	18
622	High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. <i>International Journal of Biological Sciences</i> , 2017, 13, 1172-1179.	6.4	45
623	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 433-442.	1.9	15
624	Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma. <i>Journal of Cancer</i> , 2017, 8, 3166-3172.	2.5	41
625	Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5745-5754.	2.0	14
626	Type IÎ³ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-Î²B. <i>Oncotarget</i> , 2017, 8, 42414-42427.	1.8	26
627	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	2.0	12
628	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3697-3708.	2.0	6
629	Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model. <i>PLoS ONE</i> , 2017, 12, e0178479.	2.5	112
630	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. <i>PLoS ONE</i> , 2017, 12, e0181598.	2.5	31

#	ARTICLE	IF	CITATIONS
631	Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PLoS ONE, 2017, 12, e0189697.	2.5	40
632	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer, 2017, 17, 618.	2.6	42
633	Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer, 2017, 17, 690.	2.6	41
634	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. Cancer Cell International, 2017, 17, 105.	4.1	38
635	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. Journal of Translational Medicine, 2017, 15, 244.	4.4	73
636	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology and Oncology, 2017, 10, 146.	17.0	77
637	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
638	Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. , 2017, 5, 83.		46
640	Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chinese Journal of Cancer, 2017, 36, 61.	4.9	42
641	Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurologia Medico-Chirurgica, 2017, 57, 321-330.	2.2	16
642	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget, 2017, 8, 66293-66304.	1.8	11
643	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget, 2017, 8, 90532-90544.	1.8	89
644	High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget, 2017, 8, 18021-18030.	1.8	46
645	Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer. Oncotarget, 2017, 8, 58199-58209.	1.8	10
646	Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget, 2017, 8, 49702-49712.	1.8	84
647	Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. Oncotarget, 2017, 8, 96649-96655.	1.8	22
648	Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. Oncotarget, 2017, 8, 67094-67103.	1.8	47
649	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences, 2017, 1, 471-486.	2.6	5

#	ARTICLE	IF	CITATIONS
650	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017, 8, 63901-63910.	1.8	30
651	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 15-29.	0.4	4
652	Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2017, 4, 127-135.	1.6	156
653	Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. <i>Journal of Cancer</i> , 2017, 8, 332-344.	2.5	20
654	Chemotherapy for hepatocellular carcinoma: The present and the future. <i>World Journal of Hepatology</i> , 2017, 9, 907.	2.0	142
655	Systemic treatment of hepatocellular carcinoma: Past, present and future. <i>World Journal of Hepatology</i> , 2017, 9, 797.	2.0	57
656	Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1101-1110.	2.0	13
657	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2017, 7, 23.	2.6	13
658	The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis. <i>Postepy Dermatologii i Alergologii</i> , 2017, 5, 405-417.	0.9	32
659	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. <i>Oncotarget</i> , 2017, 8, 91779-91794.	1.8	298
660	PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 24644-24651.	1.8	146
661	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	1.8	42
662	Biomarkers for Checkpoint Inhibition. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 205-209.	3.8	11
663	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. <i>Oncotarget</i> , 2017, 8, 90123-90131.	1.8	89
664	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. <i>Oncotarget</i> , 2017, 8, 3197-3205.	1.8	53
665	Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. <i>Oncotarget</i> , 2017, 8, 58887-58902.	1.8	22
666	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	1.8	68
667	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. <i>Translational Research</i> , 2018, 196, 62-70.	5.0	9

#	ARTICLE	IF	CITATIONS
668	Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 815-824.	2.8	53
669	The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Esophagus, 2018, 15, 103-108.	1.9	14
670	Gastric Carcinomas With Lymphoid Stroma. American Journal of Surgical Pathology, 2018, 42, 453-462.	3.7	37
671	Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. Nature Communications, 2018, 9, 948.	12.8	369
672	CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. Tumor Biology, 2018, 40, 101042831876042.	1.8	22
673	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. Expert Review of Clinical Pharmacology, 2018, 11, 345-359.	3.1	27
674	The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1011-1022.	4.2	36
675	Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. Journal of Dental Research, 2018, 97, 622-626.	5.2	16
677	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treatment Reviews, 2018, 65, 54-64.	7.7	51
678	Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Seminars in Cancer Biology, 2018, 52, 189-197.	9.6	112
679	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. Journal of Neuro-Oncology, 2018, 139, 251-259.	2.9	16
680	Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1204-1210.	1.3	64
681	Are There New Chemotherapy Drugs Behind the Corner?, 2018, , 355-358.		0
682	Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma. Histopathology, 2018, 73, 397-406.	2.9	54
683	Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis. Journal of Surgical Oncology, 2018, 117, 1405-1412.	1.7	4
684	Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver International, 2018, 38, 976-987.	3.9	166
685	Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. Oncogene, 2018, 37, 3672-3685.	5.9	13
686	Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Modern Pathology, 2018, 31, 1282-1290.	5.5	39

#	ARTICLE	IF	CITATIONS
687	T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	229
688	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	16.8	827
689	The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China. <i>Medicine (United States)</i> , 2018, 97, e0276.	1.0	5
691	PD-L1 expression in inflammatory myofibroblastic tumors. <i>Modern Pathology</i> , 2018, 31, 1155-1163.	5.5	15
692	Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. <i>Melanoma Research</i> , 2018, 28, 89-95.	1.2	13
693	Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2018, 28, 349-361.	4.5	37
694	Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma. <i>EBioMedicine</i> , 2018, 28, 105-113.	6.1	28
695	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , 2018, 69, 301-318.	12.2	432
696	Pathogenesis of non-functioning pituitary adenomas. <i>Pituitary</i> , 2018, 21, 130-137.	2.9	16
698	The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. <i>Medical Oncology</i> , 2018, 35, 25.	2.5	124
699	Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. <i>Oncolimmunology</i> , 2018, 7, e1435227.	4.6	16
700	Role of immune-checkpoint inhibitors in lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346581775007.	2.6	88
701	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.3	3
702	Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. <i>Cut</i> , 2018, 67, 1168-1180.	12.1	139
703	Emerging Biomarkers in Cutaneous Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 203-218.	3.8	35
704	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. <i>American Journal of Clinical Pathology</i> , 2018, 149, 253-261.	0.7	22
705	Immune-based therapies for metastatic prostate cancer: an update. <i>Immunotherapy</i> , 2018, 10, 283-298.	2.0	9
710	Microsatellite instability status determined by next-generation sequencing and compared with <sc>PD</sc> and tumor mutational burden in 11,348 patients. <i>Cancer Medicine</i> , 2018, 7, 746-756.	2.8	348

#	ARTICLE	IF	CITATIONS
711	Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. <i>Nature Protocols</i> , 2018, 13, 335-357.	12.0	32
712	Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-L1-targeted therapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26960.	1.5	44
713	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1296-1304.	7.0	146
714	High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients. <i>Liver International</i> , 2018, 38, 1449-1458.	3.9	36
715	PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy. <i>Cancer Journal (Sudbury, Mass)</i> 2018, 24, 90-98.	2.0	90
716	Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. <i>Clinical and Experimental Medicine</i> , 2018, 18, 165-175.	3.6	41
717	Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. <i>Modern Pathology</i> , 2018, 31, 623-632.	5.5	102
718	Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, 521-532.	1.1	119
719	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	3.7	23
720	Challenges in Colorectal Cancer: From Vaccines to Macrophage Repolarization. , 2018, , 621-639.		0
721	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. <i>Seminars in Cancer Biology</i> , 2018, 52, 241-252.	9.6	12
722	Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. <i>OncolImmunology</i> , 2018, 7, e1417721.	4.6	33
723	Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. <i>Scientific Reports</i> , 2018, 8, 105.	3.3	47
724	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. <i>Annals of Diagnostic Pathology</i> , 2018, 33, 62-68.	1.3	4
725	The Basic Concepts in Cancer Immunology and Immunotherapy. , 2018, , 1-19.		3
726	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. <i>Targeted Oncology</i> , 2018, 13, 125-140.	3.6	19
727	A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. <i>Seminars in Cancer Biology</i> , 2018, 52, 158-165.	9.6	4
728	Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. <i>OncolImmunology</i> , 2018, 7, e1356144.	4.6	113

#	ARTICLE	IF	CITATIONS
729	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. AAPS Journal, 2018, 20, 66.	4.4	10
730	Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opinion on Therapeutic Targets, 2018, 22, 547-557.	3.4	90
731	Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors. Medicine (United States), 2018, 97, e9617.	1.0	56
732	Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma. JAMA Dermatology, 2018, 154, 621.	4.1	7
733	Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39â€™™: An analysis of safety and immune response. Clinical Immunology, 2018, 192, 6-13.	3.2	8
734	Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma. Modern Pathology, 2018, 31, 1201-1210.	5.5	19
735	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treatment Reviews, 2018, 65, 78-86.	7.7	32
736	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity, 2018, 48, 417-433.	14.3	416
737	Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel. ACS Nano, 2018, 12, 3295-3310.	14.6	143
738	Nivolumab in squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy, 2018, 18, 409-420.	2.4	9
739	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the <i>FAMI-L1</i> study. Immunotherapy, 2018, 10, 643-655.	2.0	15
740	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. American Journal of Pathology, 2018, 188, 1478-1485.	3.8	119
741	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. European Journal of Cancer, 2018, 94, 179-186.	2.8	82
743	Association of PD-L1 and HIF-1Î± Coexpression with Poor Prognosis in Hepatocellular Carcinoma. Translational Oncology, 2018, 11, 559-566.	3.7	52
744	Biological predictors of radiosensitivity in head and neck squamous cell carcinoma. Clinical Oral Investigations, 2018, 22, 189-200.	3.0	29
745	Fading With Time of PD-L1 Immunoreactivity in Nonâ€™“Small Cells Lung Cancer Tissues: A Methodological Study. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 489-494.	1.2	38
746	PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics, 2018, 70, 73-86.	2.4	100
747	PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. Journal of Clinical Pathology, 2018, 71, 46-51.	2.0	17

#	ARTICLE	IF	CITATIONS
748	Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Nonâ€‘Small Cell Lung Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 83-93.	1.2	124
749	Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency. International Journal of Gynecological Cancer, 2018, 28, 59-68.	2.5	38
750	Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clinical Cancer Research, 2018, 24, 407-419.	7.0	203
751	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Nonâ€‘Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 334-340.	7.0	323
752	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene. Gene, 2018, 638, 20-25.	2.2	87
753	Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. Clinical Cancer Research, 2018, 24, 592-599.	7.0	75
754	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Seminars in Cancer Biology, 2018, 52, 216-227.	9.6	14
755	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular and Molecular Life Sciences, 2018, 75, 689-713.	5.4	351
756	Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunology, Immunotherapy, 2018, 67, 141-151.	4.2	58
757	Programmed cell death ligand 1 (PDâ€‘L1) expression is not a predominant feature in Ewing sarcomas. Pediatric Blood and Cancer, 2018, 65, e26719.	1.5	39
758	Immunotherapy and Lung Cancer. , 2018, , 501-511.e3.		2
759	The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma. American Journal of Surgical Pathology, 2018, 42, 183-191.	3.7	63
760	Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. Modern Pathology, 2018, 31, 101-110.	5.5	38
761	Immune Checkpoint PDâ€‘1/PDâ€‘L1: Is There Life Beyond Antibodies?. Angewandte Chemie - International Edition, 2018, 57, 4840-4848.	13.8	109
762	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. OncoImmunology, 2018, 7, e1395996.	4.6	90
763	Atezolizumab in urothelial bladder carcinoma. Future Oncology, 2018, 14, 331-341.	2.4	10
764	Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. Clinical Cancer Research, 2018, 24, 2035-2043.	7.0	75
765	Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy. Clinical Breast Cancer, 2018, 18, e237-e244.	2.4	39

#	ARTICLE	IF	CITATIONS
766	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. Expert Opinion on Investigational Drugs, 2018, 27, 55-70.	4.1	5
767	PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine. International Journal of Cancer, 2018, 142, 2106-2117.	5.1	43
768	Using <scp>MRI</scp> cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. Magnetic Resonance in Medicine, 2018, 80, 304-316.	3.0	30
769	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. European Journal of Cancer, 2018, 88, 67-76.	2.8	15
770	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. Seminars in Cancer Biology, 2018, 52, 53-65.	9.6	58
771	Der Immuncheckpoint PD-1/PD-L1: Gibt es Therapieoptionen jenseits der Antikörper?. Angewandte Chemie, 2018, 130, 4932-4940.	2.0	4
772	Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer, 2018, 124, 248-261.	4.1	94
773	Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. Frontiers of Medicine, 2018, 12, 229-235.	3.4	53
774	Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Human Pathology, 2018, 72, 135-143.	2.0	15
775	Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. American Journal of Reproductive Immunology, 2018, 79, e12795.	1.2	89
776	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. Current Cancer Research, 2018, , 243-280.	0.2	0
777	Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types. Cancer Immunology Research, 2018, 6, 87-97.	3.4	106
778	Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB Journal, 2018, 32, 1537-1549.	0.5	260
779	Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Cancer Letters, 2018, 414, 166-173.	7.2	207
780	Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. Seminars in Cancer Biology, 2018, 52, 166-177.	9.6	11
781	PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Molecular Diagnosis and Therapy, 2018, 22, 1-10.	3.8	139
782	Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Human Pathology, 2018, 71, 91-99.	2.0	102
783	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 1260-1270.	7.0	289

#	ARTICLE	IF	CITATIONS
784	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. JCI Insight, 2018, 3, .	5.0	49
785	Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis. Anti-Cancer Drugs, 2018, 29, 904-910.	1.4	32
787	Gene Expression Profiles of Programmed Death-1 (+) Lymphocytes in Peripheral Blood Reveal their Significance in Tumor Immunity of T Cell Non-Hodgkin Lymphoma. Journal of Blood & Lymph, 2018, 08, .	0.0	0
788	Immune profiling of microsatellite instability-high and polymerase Îµ (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. Journal of Gastrointestinal Oncology, 2018, 9, 404-415.	1.4	49
789	Implementing tumor mutational burden (TMB) analysis in routine diagnosticsâ€”a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	2.8	152
791	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. World Journal of Gastroenterology, 2018, 24, 3583-3616.	3.3	118
792	Tumor microenvironment classification based on Tâ€”cell infiltration and PDâ€”L1 in patients with mismatch repairâ€”proficient and â€”deficient colorectal cancer. Oncology Letters, 2018, 17, 2335-2343.	1.8	8
793	A novel indication to treat distinct types of tumors with PD-1 blockade based on mismatch-repair deficiency. Annals of Research Hospitals, 2018, 2, 2-2.	0.0	1
794	Immune checkpoint inhibitors and radiotherapyâ€”concept and review of current literature. Annals of Translational Medicine, 2018, 6, 155-155.	1.7	16
795	Clinicopathological analysis of primary intestinal diffuse large Bâ€”cell lymphoma: Prognostic evaluation of CD5, PDâ€”L1, and Epsteinâ€”Barr virus on tumor cells. Cancer Medicine, 2018, 7, 6051-6063.	2.8	27
796	A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer. OncoTargets and Therapy, 2018, Volume 11, 7691-7697.	2.0	6
797	Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129.		95
798	Combination of PD-1 blockade and RetroNectin^{Â®}-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. Immunotherapy, 2018, 10, 1315-1323.	2.0	6
799	The Identification of Immunological Biomarkers in Kidney Cancers. Frontiers in Oncology, 2018, 8, 456.	2.8	40
800	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. Current Molecular Medicine, 2018, 17, 527-540.	1.3	20
801	Therapeutic Targets for Adrenocortical Carcinoma in the Genomics Era. Journal of the Endocrine Society, 2018, 2, 1259-1274.	0.2	38
802	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. Current Treatment Options in Oncology, 2018, 19, 70.	3.0	17
803	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nature Communications, 2018, 9, 4664.	12.8	331

#	ARTICLE	IF	CITATIONS
804	New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. <i>Oncotarget</i> , 2018, 9, 10635-10649.	1.8	41
805	A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 3017.	4.8	8
806	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 40.	5.2	36
807	The clinical promise of immunotherapy in triple-negative breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6823-6833.	1.9	113
808	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2018, 8, 17812.	3.3	39
809	Organoid Modeling of the Tumor Immune Microenvironment. <i>Cell</i> , 2018, 175, 1972-1988.e16.	28.9	870
810	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	8.2	121
811	Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2140.	4.8	92
812	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2857-2873.	4.3	10
813	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. <i>Trends in Biochemical Sciences</i> , 2018, 43, 1014-1032.	7.5	151
814	Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. <i>Cancer Immunology Research</i> , 2018, 6, 1122-1128.	3.4	81
815	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. <i>Frontiers in Pharmacology</i> , 2018, 9, 1050.	3.5	48
816	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. <i>Science</i> , 2018, 362, .	12.6	1,575
817	Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. <i>Frontiers in Oncology</i> , 2018, 8, 435.	2.8	18
818	Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy. <i>Cancers</i> , 2018, 10, 374.	3.7	19
820	PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 580-588.	8.2	388
821	Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation. <i>Oncology Reports</i> , 2018, 40, 3370-3380.	2.6	6
822	Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1845-1851.	4.2	28

#	ARTICLE	IF	CITATIONS
823	11 Role of Dermatopathology in the Surgical Management of Skin Cancer. , 2018, , .		0
824	Targeting Toll-Like Receptors for Cancer Therapy. Targeted Oncology, 2018, 13, 583-598.	3.6	88
825	Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer. Cancer Immunology Research, 2018, 6, 1426-1441.	3.4	66
826	PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. Breast Journal, 2018, 24, 911-919.	1.0	65
827	PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget, 2018, 9, 8584-8596.	1.8	53
828	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survival. Oncoimmunology, 2018, 7, e1509820.	4.6	80
829	Precision medicine in cholangiocarcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 40-40.	3.0	61
830	Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines, 2018, 6, 14.	3.2	66
831	PD-L1 expression in meningiomas. Journal of Clinical Neuroscience, 2018, 57, 149-151.	1.5	20
832	PD-L1 Expression Heterogeneity in Non-“Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. Journal of Thoracic Oncology, 2018, 13, 1113-1120.	1.1	135
833	Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head and Neck, 2018, 40, 2007-2019.	2.0	47
834	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. Journal of Molecular Biology, 2018, 430, 2014-2029.	4.2	42
835	JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. Clinical Breast Cancer, 2018, 18, e1205-e1215.	2.4	46
836	The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma. Archives of Pathology and Laboratory Medicine, 2018, 142, 719-720.	2.5	1
838	IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Modern Pathology, 2018, 31, 1513-1522.	5.5	68
839	PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. PLoS ONE, 2018, 13, e0194594.	2.5	19
840	Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors. BioMed Research International, 2018, 2018, 1-7.	1.9	19
841	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	1.2	135

#	ARTICLE	IF	CITATIONS
842	Immunotherapies: Exploiting the Immune System for Cancer Treatment. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	2.2	89
843	Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 171-183.	2.3	17
844	CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. <i>Cancer Research</i> , 2018, 78, 4692-4703.	0.9	140
845	Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. <i>Oncolmunology</i> , 2018, 7, e1484982.	4.6	33
846	Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 826-836.	1.0	8
847	Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. <i>Future Oncology</i> , 2018, 14, 2683-2690.	2.4	1
848	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of UOEH</i> , 2018, 40, 173-189.	0.6	45
849	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1569-1576.	1.1	206
850	Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. <i>Translational Oncology</i> , 2018, 11, 1171-1187.	3.7	94
851	Sno-derived RNAs are prevalent molecular markers of cancer immunity. <i>Oncogene</i> , 2018, 37, 6442-6462.	5.9	28
852	Biomarkers of response to immune checkpoint blockade in cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 108-120.	4.4	61
853	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. <i>Theranostics</i> , 2018, 8, 3559-3570.	10.0	85
854	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. <i>Oncolmunology</i> , 2018, 7, e1475874.	4.6	20
855	Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. <i>Surgery</i> , 2018, 164, 960-964.	1.9	15
856	Immunotherapy in Glioblastoma. <i>World Neurosurgery</i> , 2018, 116, 518-528.	1.3	31
857	Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2018, 24, 5368-5380.	7.0	189
858	Construction of an anti-programmed death-ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. <i>Oncology Letters</i> , 2018, 16, 157-166.	1.8	9
859	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. <i>Cell Death and Disease</i> , 2018, 9, 810.	6.3	38

#	ARTICLE	IF	CITATIONS
860	PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma. Journal of Cancer, 2018, 9, 2224-2231.	2.5	17
861	Immune Checkpoint Blockade in Hematologic Malignancies. , 2018, , 1583-1587.		1
862	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. Journal of Cancer, 2018, 9, 205-212.	2.5	9
863	Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors. Frontiers in Immunology, 2018, 8, 1993.	4.8	22
864	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond. Frontiers in Immunology, 2018, 9, 1474.	4.8	174
865	Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. Frontiers in Oncology, 2018, 8, 71.	2.8	22
866	Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. Frontiers in Oncology, 2018, 8, 185.	2.8	60
867	The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. Breast Cancer Research, 2018, 20, 71.	5.0	55
868	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines, 2018, 6, 26.	3.2	16
869	PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PLoS ONE, 2018, 13, e0196464.	2.5	20
870	Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. Human Pathology, 2018, 82, 39-45.	2.0	2
871	Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. International Journal of Molecular Sciences, 2018, 19, 739.	4.1	44
872	Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. International Journal of Molecular Sciences, 2018, 19, 1389.	4.1	77
873	Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. Journal of Translational Medicine, 2018, 16, 195.	4.4	13
874	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). , 2018, 6, 39.		329
875	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3+ T Cell-Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research, 2018, 6, 1069-1081.	3.4	67
876	A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. Clinical and Experimental Medicine, 2018, 18, 555-562.	3.6	25
877	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Annals of Oncology, 2018, 29, 1807-1813.	1.2	261

#	ARTICLE	IF	CITATIONS
878	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. <i>Future Oncology</i> , 2018, 14, 41-60.	2.4	12
879	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	5.1	15
880	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	5.3	64
881	Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity. <i>Scientific Reports</i> , 2018, 8, 7012.	3.3	89
882	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. <i>British Journal of Cancer</i> , 2018, 119, 538-545.	6.4	111
883	Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 4.	2.6	85
884	Integrating oncolytic viruses in combination cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 498-513.	22.7	448
885	Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. <i>Oncolmunology</i> , 2018, 7, e1465165.	4.6	59
886	Functional immune characterization of HIV-associated non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1486-1488.	1.2	10
887	Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1 α and STAT3. <i>Pharmacological Research</i> , 2018, 135, 166-180.	7.1	51
888	Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. <i>Journal of Cancer</i> , 2018, 9, 129-134.	2.5	11
889	Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 499.e9-499.e16.	1.6	50
890	Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. <i>Cancer Medicine</i> , 2018, 7, 4517-4529.	2.8	34
891	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 101, 236-243.	2.8	100
892	Preliminary application of ^{125}I -nivolumab to detect PD-1 expression in colon cancer via SPECT. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 318, 1237-1242.	1.5	7
893	Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. <i>Molecular Pharmaceutics</i> , 2018, 15, 4426-4433.	4.6	37
894	Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer. <i>Journal of Ovarian Research</i> , 2018, 11, 43.	3.0	60
895	Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer. <i>Anticancer Research</i> , 2018, 38, 3367-3373.	1.1	46

#	ARTICLE	IF	CITATIONS
896	Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Nonâ€“Small Cell Lung Cancer. American Journal of Surgical Pathology, 2018, 42, 1090-1094.	3.7	27
897	Indoleamine-2,3-Dioxygenase in Nonâ€“Small Cell Lung Cancer. American Journal of Surgical Pathology, 2018, 42, 1216-1223.	3.7	36
898	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640.	2.5	5
899	Photothermal-Activatable Fe ₃ O ₄ Superparticle Nanodrug Carriers with PD-L1 Immune Checkpoint Blockade for Anti-metastatic Cancer Immunotherapy. ACS Applied Materials & Interfaces, 2018, 10, 20342-20355.	8.0	112
900	Programmed death receptor Ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients. Acta Ophthalmologica, 2019, 97, e390-e396.	1.1	14
901	Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Clinical Cancer Research, 2019, 25, 957-966.	7.0	37
902	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cellular and Molecular Immunology, 2019, 16, 28-39.	10.5	57
903	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. Journal of Oncology Pharmacy Practice, 2019, 25, 663-673.	0.9	8
904	Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery, 2019, 85, 280-289.	1.1	22
905	PDâ€“L1 Expression and Tumorâ€“Infiltrating Lymphocytes in Highâ€“Risk and Metastatic Cutaneous Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2019, 160, 93-99.	1.9	23
906	Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. Future Oncology, 2019, 15, 3171-3184.	2.4	11
907	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatmentâ€“Review. Frontiers in Immunology, 2019, 10, 2043.	4.8	7
908	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Advances in Therapy, 2019, 36, 2638-2678.	2.9	145
909	Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. Frontiers in Immunology, 2019, 10, 1767.	4.8	44
910	Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Frontiers in Immunology, 2019, 10, 1848.	4.8	56
911	Pseudoprogression: an indicator for cure in combined immunotherapy?. Immunotherapy, 2019, 11, 1087-1093.	2.0	6
912	Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study. Translational Lung Cancer Research, 2019, 8, 258-267.	2.8	17
913	Effect and biomarker of Nivolumab for nonâ€“small-cell lung cancer. Biomedicine and Pharmacotherapy, 2019, 117, 109199.	5.6	22

#	ARTICLE	IF	CITATIONS
914	Usefulness of the nCounter Analysis System to Monitor Immune-related Biomarkers in PBMCs During Anti-PD-1 Therapy. <i>Anticancer Research</i> , 2019, 39, 4517-4523.	1.1	1
915	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1195.	7.1	431
916	Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019, 2, 100-109.	3.3	11
917	Acral Lentiginous Melanoma. , 2019, , 1-28.		1
918	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 4018-4025.	1.8	118
919	Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. <i>Cancer Investigation</i> , 2019, 37, 265-274.	1.3	31
920	Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness. <i>BMC Cancer</i> , 2019, 19, 687.	2.6	15
921	Stealth surface driven accumulation of “Trojan Horse” for tumor hypoxia relief in combination with targeted cancer therapy. <i>Chemical Engineering Journal</i> , 2019, 378, 122252.	12.7	23
922	Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 1020-1030.	4.1	86
923	Cell-Penetrating Peptide Enhanced Antigen Presentation for Cancer Immunotherapy. <i>Bioconjugate Chemistry</i> , 2019, 30, 2115-2126.	3.6	23
924	MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications. <i>Pathology Research and Practice</i> , 2019, 215, 152552.	2.3	12
925	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2019, 21, 79.	4.4	53
926	IL-9 Exerts Antitumor Effects in Colon Cancer and Transforms the Tumor Microenvironment <i>In Vivo</i> . <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381985773.	1.9	29
927	Immune checkpoint blockade in glioma. , 2019, , 387-396.		0
928	Vaccine Therapies for Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 353-367.	1.5	24
929	Supporting the stratification of non-small cell lung carcinoma for Anti PD-L1 immunotherapy with digital image registration. , 2019, , .		1
930	ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer. <i>Cells</i> , 2019, 8, 678.	4.1	73
931	Application of immune repertoire sequencing in cancer immunotherapy. <i>International Immunopharmacology</i> , 2019, 74, 105688.	3.8	7

#	ARTICLE	IF	CITATIONS
932	Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. International Journal of Molecular Sciences, 2019, 20, 5129.	4.1	19
933	Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1779-1790.	4.2	10
934	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers, 2019, 11, 1554.	3.7	73
935	The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Frontiers in Oncology, 2019, 9, 897.	2.8	29
936	Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Scientific Reports, 2019, 9, 14356.	3.3	56
937	Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives. Cancers, 2019, 11, 1420.	3.7	9
938	Immunomodulatory aspects in the progression and treatment of oral malignancy. Japanese Dental Science Review, 2019, 55, 113-120.	5.1	33
939	Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. Seminars in Immunology, 2019, 42, 101306.	5.6	17
940	Characterization of intratumoral and circulating IL-10-producing B cells in gastric cancer. Experimental Cell Research, 2019, 384, 111652.	2.6	22
941	The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes. Cancer Medicine, 2019, 8, 7207-7218.	2.8	35
942	Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. BMC Cancer, 2019, 19, 1022.	2.6	11
943	PD-L1/PD-1 Axis in Glioblastoma Multiforme. International Journal of Molecular Sciences, 2019, 20, 5347.	4.1	115
944	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. Journal of Clinical Oncology, 2019, 37, 3546-3555.	1.6	78
945	PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma. Cancer Immunology Research, 2019, 7, 1891-1899.	3.4	66
946	Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. International Immunopharmacology, 2019, 77, 105999.	3.8	43
947	Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1. Protein Engineering, Design and Selection, 2019, 32, 231-240.	2.1	6
948	Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Neuropathology, 2019, 39, 413-424.	1.2	14
949	Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition. , 2019, 7, 277.		53

#	ARTICLE	IF	CITATIONS
950	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
951	Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Medicine, 2019, 8, 7322-7329.	2.8	46
952	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. Oncologist, 2019, 24, e1055-e1069.	3.7	36
953	Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Seminars in Cancer Biology, 2019, 59, 236-250.	9.6	200
954	Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. Oncology Letters, 2019, 18, 1775-1785.	1.8	8
955	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes and Diseases, 2019, 6, 232-246.	3.4	44
956	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
957	Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. Frontiers in Oncology, 2019, 9, 883.	2.8	40
958	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. Cancer Immunology Research, 2019, 7, 1574-1579.	3.4	33
959	PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. OncoImmunology, 2019, 8, e1655362.	4.6	39
960	Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1585-1596.	4.2	37
961	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. , 2019, 7, 254.		14
962	Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune "Defects" in the Tumor Microenvironment. Journal of Clinical Medicine, 2019, 8, 1472.	2.4	56
963	Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1527-1535.	4.2	30
964	Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies. Frontiers in Immunology, 2019, 10, 1876.	4.8	35
965	Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma Patients Using Contrast-Enhanced Computed Tomography. Annals of Surgical Oncology, 2019, 26, 4537-4547.	1.5	62
966	Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. Tumori, 2019, 105, 465-473.	1.1	4
967	<p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>. OncoTargets and Therapy, 2019, Volume 12, 7281-7288.	2.0	11

#	ARTICLE	IF	CITATIONS
968	Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , 2019, 46, 100644.	14.4	133
969	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862.	7.2	131
970	Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. <i>Cancer Research</i> , 2019, 79, 1113-1123.	0.9	45
971	Successful treatment of unresectable recurrent programmed death ligand 1 moderately expressing malignant melanoma of the nasal cavity with pembrolizumab monotherapy. <i>Journal of Dermatology</i> , 2019, 46, e260.	1.2	1
972	The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1494.	3.5	24
973	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. <i>Cancer Immunology Research</i> , 2019, 7, 401-413.	3.4	99
974	Efficacy and safety of nivolumab for metastatic biliary tract cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 861-867.	2.0	31
975	Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. <i>Frontiers of Medicine</i> , 2019, 13, 32-44.	3.4	25
976	Combining immunotherapies to treat non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 621-634.	2.5	2
977	Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status. <i>Journal of Cancer</i> , 2019, 10, 1745-1754.	2.5	19
978	Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression. <i>Cancer Communications</i> , 2019, 39, 1-6.	9.2	4
979	A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. <i>International Journal of Cancer</i> , 2019, 145, 2535-2546.	5.1	48
980	Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment. <i>Cancer Microenvironment</i> , 2019, 12, 149-167.	3.1	21
981	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. <i>Disease Markers</i> , 2019, 2019, 1-6.	1.3	12
982	PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. , 2019, 60, 2388.		30
983	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 54.	17.0	416
984	An integrated quantitative structure and mechanism of action-activity relationship model of human serum albumin binding. <i>Journal of Cheminformatics</i> , 2019, 11, 38.	6.1	17
985	Pan-cancer analysis connects tumor matrisome to immune response. <i>Npj Precision Oncology</i> , 2019, 3, 15.	5.4	58

#	ARTICLE	IF	CITATIONS
986	Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy. <i>Theranostics</i> , 2019, 9, 2299-2314.	10.0	88
987	Prognostic role of tumour-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 69-78.	1.3	12
988	Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.3	34
989	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	28.4	879
990	Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 642.	2.4	47
991	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. <i>Journal of Pathology</i> , 2019, 249, 151-165.	4.5	80
992	Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy. <i>Cytotechnology</i> , 2019, 71, 705-722.	1.6	7
993	The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer—Ways of Enhancing Immunotherapy Action. <i>Cancers</i> , 2019, 11, 533.	3.7	37
994	Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress. <i>Frontiers in Pediatrics</i> , 2019, 7, 141.	1.9	73
995	Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. <i>Molecular Imaging</i> , 2019, 18, 153601211982998.	1.4	55
996	Clinicopathologic characteristics, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 113-118.	2.5	8
997	rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2082.	4.1	6
998	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 360.	2.6	52
999	Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. <i>PLoS ONE</i> , 2019, 14, e0215381.	2.5	73
1000	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	5.0	52
1001	Current and emerging systemic therapies for cutaneous metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1135-1152.	1.8	33
1002	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 393-404.	2.4	26
1003	Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. <i>Hematology</i> , 2019, 24, 392-398.	1.5	29

#	ARTICLE	IF	CITATIONS
1004	Advances in pancreatic cancer biomarkers. <i>Oncology Reviews</i> , 2019, 13, 410.	1.8	87
1005	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 805-812.	3.4	22
1006	MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	1.5	21
1007	Medical treatment for cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 123-142.	3.9	69
1008	The neoepitope landscape of breast cancer: implications for immunotherapy. <i>BMC Cancer</i> , 2019, 19, 200.	2.6	68
1009	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 328-344.	6.8	160
1010	Clinicopathological, immune and molecular correlates of <i>PD-L2</i> methylation in gastric adenocarcinomas. <i>Epigenomics</i> , 2019, 11, 639-653.	2.1	17
1011	Microsatellite instability in endometrial cancer: New purpose for an old test. <i>Cancer</i> , 2019, 125, 2154-2163.	4.1	23
1012	Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. <i>Cancer Treatment Reviews</i> , 2019, 75, 27-38.	7.7	32
1013	An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13330-13341.	2.6	16
1014	Targeting immune cells for cancer therapy. <i>Redox Biology</i> , 2019, 25, 101174.	9.0	151
1015	Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer. <i>International Journal of Biological Markers</i> , 2019, 34, 132-138.	1.8	33
1016	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , 2019, 11, 515-529.	2.0	17
1017	Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 30.	3.0	24
1018	Emerging biomarkers in ovarian granulosa cell tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 560-565.	2.5	13
1019	Integrative immunologic and genomic characterization of brain metastasis from ovarian/peritoneal cancer. <i>Pathology Research and Practice</i> , 2019, 215, 152404.	2.3	9
1020	TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers. <i>Modern Pathology</i> , 2019, 32, 1168-1179.	5.5	27
1021	Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9. <i>Seminars in Liver Disease</i> , 2019, 39, 261-274.	3.6	21

#	ARTICLE	IF	CITATIONS
1022	Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. Respiratory Medicine Case Reports, 2019, 26, 310-314.	0.4	24
1023	Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Nano Letters, 2019, 19, 2774-2783.	9.1	155
1024	<p>>Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis</p>>. Drug Design, Development and Therapy, 2019, Volume 13, 523-538.	4.3	23
1025	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. Cancers, 2019, 11, 223.	3.7	18
1026	Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study. Clinical and Translational Oncology, 2019, 21, 1093-1103.	2.4	7
1027	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer, 2019, 19, 133-150.	28.4	1,657
1028	Therapeutic Cancer Vaccines"T Cell Responses and Epigenetic Modulation. Frontiers in Immunology, 2018, 9, 3109.	4.8	26
1029	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 87.	8.6	213
1030	Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus. Viruses, 2019, 11, 156.	3.3	32
1031	Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Science Translational Medicine, 2019, 11, .	12.4	169
1032	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
1033	Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology, 2019, 8, e1564505.	4.6	118
1034	CTHRC1 and PD"1/PD"L1 expression predicts tumor recurrence in prostate cancer. Molecular Medicine Reports, 2019, 20, 4244-4252.	2.4	11
1035	Safety and Efficacy in Relapsed or Refractory Classic Hodgkin"s Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. BioMed Research International, 2019, 2019, 1-13.	1.9	5
1036	9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Scientific Reports, 2019, 9, 19977.	3.3	32
1037	Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomedical Research, 2019, 40, 243-250.	0.9	26
1038	Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nature Communications, 2019, 10, 5421.	12.8	151
1039	Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. Scientific Reports, 2019, 9, 17252.	3.3	20

#	ARTICLE	IF	CITATIONS
1040	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988554.	3.2	25
1041	PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. American Journal of Dermatopathology, 2019, 41, 539-565.	0.6	8
1042	Precision Cancer Trials With Immunomodulatory Agents. Cancer Journal (Sudbury, Mass), 2019, 25, 287-295.	2.0	3
1043	Primary tumor resection for initially staged IV breast cancer. Medicine (United States), 2019, 98, e16773.	1.0	7
1044	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. Journal of Immunotherapy, 2019, 42, 269-273.	2.4	10
1045	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors. American Journal of Surgical Pathology, 2019, 43, 792-801.	3.7	28
1046	<p><p>Comparison of Double Sleeve Lobectomy by Uniportal Video-Assisted Thoracic Surgery (VATS) and Thoracotomy for NSCLC Treatment<p>. Cancer Management and Research, 2019, Volume 11, 10167-10174.	1.9	15
1047	Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Veterinary and Comparative Oncology, 2019, 17, 49-60.	1.8	33
1048	Molecular characterization of cancers with NTRK gene fusions. Modern Pathology, 2019, 32, 147-153.	5.5	360
1049	The Current Status of Immunotherapy in Thoracic Malignancies. , 2019, , 45-75.		0
1050	Gynecologic Malignancies. , 2019, , 135-155.		0
1051	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
1052	Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Review of Anticancer Therapy, 2019, 19, 105-119.	2.4	107
1053	Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast. Breast Journal, 2019, 25, 175-176.	1.0	3
1054	<scp>PD</scp> and <scp>IDO</scp> expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. Histopathology, 2019, 74, 256-268.	2.9	42
1055	Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncology, 2019, 88, 95-101.	1.5	54
1056	The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. Lung Cancer, 2019, 127, 153-163.	2.0	77
1057	Calnexin Impairs the Antitumor Immunity of CD4+ and CD8+ T Cells. Cancer Immunology Research, 2019, 7, 123-135.	3.4	30

#	ARTICLE	IF	CITATIONS
1058	The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2019, 20, e195-e207.	2.6	11
1059	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	1.1	68
1060	Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 255-264.	2.3	34
1061	Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer. <i>Cancer Letters</i> , 2019, 443, 1-12.	7.2	27
1062	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 150-161.	3.4	29
1063	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 57-67.	1.2	167
1064	Radiotherapy and immunotherapy: a synergistic effect in cancer care. <i>Medical Journal of Australia</i> , 2019, 210, 47-53.	1.7	53
1065	Population Pharmacokinetics and Exposure â€” Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 364-373.	2.0	11
1066	The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 175-188.	4.2	25
1067	Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 201-211.	4.2	46
1068	Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma. <i>American Journal of Dermatopathology</i> , 2019, 41, 180-187.	0.6	1
1069	Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect. <i>European Radiology</i> , 2019, 29, 4294-4302.	4.5	28
1070	Promising efficacy of SHRâ€”1210, a novel antiâ€”programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. <i>Cancer</i> , 2019, 125, 742-749.	4.1	55
1071	PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 110, 312-318.	5.6	204
1072	Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. <i>Oncogene</i> , 2019, 38, 2380-2393.	5.9	178
1073	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	47.7	237
1074	PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 546-554.	2.5	53
1075	Age-related variations in gene expression patterns of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 166-175.	1.6	8

#	ARTICLE	IF	CITATIONS
1076	Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028. <i>Gynecologic Oncology</i> , 2019, 152, 243-250.	1.4	192
1077	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.	5.1	131
1078	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2019, 18, e20-e38.	2.3	62
1079	Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. <i>Modern Pathology</i> , 2019, 32, 396-404.	5.5	41
1080	Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients. <i>Modern Pathology</i> , 2019, 32, 367-375.	5.5	31
1081	RNA In Situ Hybridization for Epstein-Barr Virus and Cytomegalovirus: Comparison With In Situ Hybridization and Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 155-159.	1.2	17
1082	The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 287-294.	1.2	17
1083	Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. <i>Pathology and Oncology Research</i> , 2019, 25, 319-325.	1.9	2
1084	Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. <i>Journal of Drug Targeting</i> , 2019, 27, 244-256.	4.4	86
1085	Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). <i>International Journal of Gynecological Pathology</i> , 2019, 38, 157-170.	1.4	34
1086	Tumor inherent interferons: Impact on immune reactivity and immunotherapy. <i>Cytokine</i> , 2019, 118, 42-47.	3.2	17
1087	The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay. <i>Pathology and Oncology Research</i> , 2020, 26, 79-89.	1.9	59
1088	<i>Cancer Immunology</i> . , 2020, , 84-96.e5.		0
1089	Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 1-9.	1.2	12
1090	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 358-366.	1.3	9
1091	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. <i>Oncologist</i> , 2020, 25, e147-e159.	3.7	220
1092	Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 1-11.	6.7	13
1093	Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases. <i>Modern Pathology</i> , 2020, 33, 138-152.	5.5	12

#	ARTICLE	IF	CITATIONS
1094	Immune checkpoints in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2020, 65, 1-12.	9.6	146
1095	Immunophenotypic Characterization and Purification of Neoplastic Cells from Lymph Nodes Involved by Tâ€Cell/Histiocyteâ€rich Large Bâ€cell Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 88-98.	1.5	6
1096	Immunologic and immunogenomic aspects of tumor progression. <i>Seminars in Cancer Biology</i> , 2020, 60, 249-261.	9.6	35
1097	Current Immunotherapeutic Strategies in Cancer. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	4
1098	Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. <i>Journal of Gastroenterology</i> , 2020, 55, 39-50.	5.1	26
1099	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repairâ€Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	1.6	1,740
1100	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in nonâ€small cell lung cancer. <i>Journal of Pathology</i> , 2020, 250, 19-29.	4.5	92
1101	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. <i>Lung Cancer</i> , 2020, 139, 1-8.	2.0	92
1102	Association of combined <scp>PD</scp>â€L1 expression and tumourâ€infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 984-994.	2.4	31
1103	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. <i>Nanoscale</i> , 2020, 12, 413-436.	5.6	49
1104	Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 21-31.	2.0	20
1105	Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1137-1144.	5.0	9
1106	A â€Noâ€Touchâ€Antibodyâ€Staining Method of Adherent Cells for Highâ€Throughput Flow Cytometry in 384â€Well Microplate Format for Cellâ€Based Drug Library Screening. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 845-851.	1.5	3
1107	Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2020, 72, 965-981.	7.3	159
1108	Efficacy of immune checkpoint inhibitors according to PDâ€L1 tumor proportion scores in nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 408-414.	1.9	12
1109	Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. <i>American Journal of Surgical Pathology</i> , 2020, 44, 378-386.	3.7	23
1110	Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Nonâ€Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e151-e163.	2.6	9
1111	Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 891-902.	2.8	28

#	ARTICLE	IF	CITATIONS
1112	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563.	6.4	59
1113	Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non-Small Cell Lung Adenocarcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 23-29.	1.2	6
1114	The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2020, 36, 74-79.	0.8	8
1115	Biomarkers that may predict response to immunotherapy in ovarian malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 84-90.	2.0	8
1116	Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 661-668.	1.2	7
1117	Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 932-941.	2.4	33
1118	Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1042-1048.	2.8	29
1119	Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. <i>World Neurosurgery</i> , 2020, 135, e187-e193.	1.3	19
1120	Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 413-420.	6.4	16
1121	LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 203-212.	1.4	26
1122	Neutrophil infiltration and whole-cell vaccine elicited by N-dihydrogalactochitosan combined with NIR phototherapy to enhance antitumor immune response and T cell immune memory. <i>Theranostics</i> , 2020, 10, 1814-1832.	10.0	30
1123	Combination Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. <i>Frontiers in Immunology</i> , 2020, 11, 568759.	4.8	79
1124	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	2.4	11
1125	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1313-1324.	2.0	5
1126	Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. <i>Thoracic Cancer</i> , 2020, 11, 3521-3527.	1.9	1
1127	Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. , 2020, 8, e000974.		49
1128	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	3.8	76
1129	Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1050-1050.	1.7	31

#	ARTICLE	IF	CITATIONS
1130	Impact of sidedness of colorectal cancer on tumor immunity. PLoS ONE, 2020, 15, e0240408.	2.5	13
1131	Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells. Molecular Therapy - Oncolytics, 2020, 19, 33-46.	4.4	13
1132	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. Oral Oncology, 2020, 109, 104977.	1.5	10
1133	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. Urologic Clinics of North America, 2020, 47, 487-510.	1.8	10
1134	Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2. Dermatologic Therapy, 2020, 33, e14035.	1.7	2
1135	Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. Scandinavian Journal of Gastroenterology, 2020, 55, 1057-1062.	1.5	15
1136	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. Frontiers in Oncology, 2020, 10, 568279.	2.8	11
1137	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review. Translational Lung Cancer Research, 2020, 9, 2120-2136.	2.8	16
1138	Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2020, 22, e555-e562.	2.6	1
1139	Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. Expert Opinion on Emerging Drugs, 2020, 25, 501-514.	2.4	7
1140	The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies. Clinical and Translational Immunology, 2020, 9, e1215.	3.8	23
1141	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
1142	Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers, 2020, 12, 3515.	3.7	5
1143	Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences, 2020, 21, 8984.	4.1	88
1144	PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome. International Journal of Molecular Sciences, 2020, 21, 9147.	4.1	9
1145	Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy. Cancers, 2020, 12, 3588.	3.7	9
1146	Analysis of Immune Microenvironment by Multiplex Immunohistochemistry Staining in Different Oral Diseases and Oral Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 555757.	2.8	12
1147	EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. Cancer Gene Therapy, 2021, 28, 864-874.	4.6	27

#	ARTICLE	IF	CITATIONS
1148	Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer. <i>Cancer Investigation</i> , 2020, 38, 406-414.	1.3	11
1149	<p>NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5975-5985.	1.9	7
1150	Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality. <i>Frontiers in Oncology</i> , 2020, 10, 1321.	2.8	22
1151	Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions. <i>Cancers</i> , 2020, 12, 2018.	3.7	5
1152	Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy. <i>Tumori</i> , 2020, 107, 030089162094038.	1.1	8
1153	Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2413-2424.	4.2	21
1154	Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1303-1307.	2.5	26
1155	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. <i>Experimental Hematology and Oncology</i> , 2020, 9, 17.	5.0	21
1156	<p>Toll-Like Receptor 9 Agonists in Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10039-10061.	2.0	74
1157	Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. <i>Journal of Bone Oncology</i> , 2020, 25, 100332.	2.4	19
1158	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. <i>ESMO Open</i> , 2020, 5, e000799.	4.5	45
1159	Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	2.2	16
1160	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. <i>Nature Communications</i> , 2020, 11, 5415.	12.8	85
1161	Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1184-1191.	3.7	18
1162	Immunotherapy via PD-L1âpresenting biomaterials leads to long-term islet graft survival. <i>Science Advances</i> , 2020, 6, eaba5573.	10.3	54
1163	Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. , 2020, 8, e001141.		31
1164	Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. <i>Journal of the American Chemical Society</i> , 2020, 142, 18874-18885.	13.7	16
1165	Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2020, 9, 1053-1066.	2.8	7

#	ARTICLE	IF	CITATIONS
1166	Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3.	16.8	203
1167	Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint. <i>RSC Chemical Biology</i> , 2020, 1, 214-224.	4.1	11
1168	Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 1455.	2.8	9
1169	Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2105-2116.	4.1	10
1170	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. <i>EBioMedicine</i> , 2020, 59, 102962.	6.1	31
1171	CD73 Is Enriched in Cutaneous Carcinomas That Invade the Orbit. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2020, 36, 247-249.	0.8	2
1172	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2495.	3.7	12
1173	PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1353-1366.	3.7	9
1174	Chronic ethanol consumption and HBV induce abnormal lipid metabolism through HBx/SWELL1/arachidonic acid signaling and activate Tregs in HBV-Tg mice. <i>Theranostics</i> , 2020, 10, 9249-9267.	10.0	20
1175	Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells. <i>Prostate Cancer</i> , 2020, 2020, 1-12.	0.6	10
1176	Immunotherapy for advanced thyroid cancers â€” rationale, current advances and future strategies. <i>Nature Reviews Endocrinology</i> , 2020, 16, 629-641.	9.6	49
1177	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. , 2020, 8, e000873.		49
1178	Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. <i>Vaccines</i> , 2020, 8, 753.	4.4	7
1179	Quality of CD8 ⁺ T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context. <i>Science Advances</i> , 2020, 6, .	10.3	24
1180	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2020, 2020, 1-14.	1.3	13
1181	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. <i>Science</i> , 2020, 370, 1328-1334.	12.6	273
1182	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. <i>Respiration</i> , 2020, 99, 903-929.	2.6	18
1183	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. <i>Cancers</i> , 2020, 12, 3173.	3.7	36

#	ARTICLE	IF	CITATIONS
1184	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	9.4	388
1185	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 569219.	3.7	59
1186	Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. <i>OncoImmunology</i> , 2020, 9, 1737385.	4.6	23
1187	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. <i>Clinical Cancer Research</i> , 2020, 26, 1141-1151.	7.0	43
1188	Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. <i>British Journal of Cancer</i> , 2020, 123, 392-402.	6.4	28
1189	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. <i>Journal of Clinical Medicine</i> , 2020, 9, 1508.	2.4	3
1190	Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: a review. <i>Child's Nervous System</i> , 2020, 36, 1635-1642.	1.1	14
1191	Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1891-1903.	4.2	62
1192	Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas. <i>Cancers of the Head & Neck</i> , 2020, 5, 6.	6.2	52
1193	Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2840-2848.	3.3	4
1194	The integration of proportion and cell counts of stromal, not intratumoral, PD-1+ tumor-infiltrating lymphocytes has prognostic significance in esophageal squamous cell carcinoma. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.4	0
1195	Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. <i>Frontiers in Medicine</i> , 2020, 7, 144.	2.6	15
1196	Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. <i>Cancers</i> , 2020, 12, 1114.	3.7	34
1197	Glioblastoma multiforme: novel therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 605-614.	3.4	36
1198	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 981-989.	3.1	20
1199	Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. <i>International Journal of Oral Science</i> , 2020, 12, 16.	8.6	108
1200	Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. <i>European Journal of Cancer Care</i> , 2020, 29, e13268.	1.5	4
1201	Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188384.	7.4	14

#	ARTICLE	IF	CITATIONS
1202	Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer. <i>Biomaterials</i> , 2020, 255, 120190.	11.4	75
1203	Immuno-Oncology, Imaging Biomarkers and Response to Chemotherapy in Cancer Treatment. , 2020, , .		0
1204	Prevalence of <i>PRKDC</i> mutations and association with response to immune checkpoint inhibitors in solid tumors. <i>Molecular Oncology</i> , 2020, 14, 2096-2110.	4.6	21
1205	Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies. <i>Nanomaterials</i> , 2020, 10, 1145.	4.1	21
1206	Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer. <i>Targeted Oncology</i> , 2020, 15, 415-428.	3.6	22
1207	Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1721.	2.4	43
1208	Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 370.	3.7	6
1209	Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 1088.	4.8	61
1210	Cancer Cellâ€™Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Antiâ€™PD-1 Therapy in Lung Adenocarcinoma. <i>Journal of Immunology</i> , 2020, 204, 2295-2307.	0.8	83
1211	The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 261.	2.8	11
1212	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. <i>Frontiers in Immunology</i> , 2020, 11, 372.	4.8	20
1213	Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1293-1305.	4.2	28
1214	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	2.4	57
1215	Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 321-329.	1.5	3
1216	Melanoma immunotherapy: strategies to overcome pharmacological resistance. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 289-304.	2.4	13
1217	Immunotherapeutic Potential of TGF-Î² Inhibition and Oncolytic Viruses. <i>Trends in Immunology</i> , 2020, 41, 406-420.	6.8	55
1218	Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. <i>Modern Pathology</i> , 2020, 33, 1182-1192.	5.5	28
1219	Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 146, 3461-3473.	5.1	39

#	ARTICLE	IF	CITATIONS
1220	Limited MOMP, ATM, and their roles in carcinogenesis and cancer treatment. Cell and Bioscience, 2020, 10, 81.	4.8	8
1221	Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy. Frontiers in Oncology, 2020, 10, 913.	2.8	29
1222	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. OncoImmunology, 2020, 9, 1761229.	4.6	22
1223	Discovery of AB680: A Potent and Selective Inhibitor of CD73. Journal of Medicinal Chemistry, 2020, 63, 11448-11468.	6.4	52
1224	Role of DNA repair defects in predicting immunotherapy response. Biomarker Research, 2020, 8, 23.	6.8	47
1225	Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. OncoTargets and Therapy, 2020, Volume 13, 5191-5198.	2.0	3
1226	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. Nanomaterials, 2020, 10, 1274.	4.1	26
1227	HLA-G: A New Immune Checkpoint in Cancer?. International Journal of Molecular Sciences, 2020, 21, 4528.	4.1	52
1228	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
1229	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Network, 2020, 20, e10.	3.6	86
1230	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology, 2022, 79, 18-43.	9.6	35
1231	Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. Science Translational Medicine, 2020, 12, .	12.4	49
1232	The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas. Pathology Research and Practice, 2020, 216, 153071.	2.3	5
1233	Medical management of meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 170, 291-302.	1.8	3
1234	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clinical Epigenetics, 2020, 12, 94.	4.1	26
1235	The 5-Whs of immunotherapy in head and neck cancer. Critical Reviews in Oncology/Hematology, 2020, 153, 103041.	4.4	13
1236	Fewer tumour-specific PD-1+CD8+ TILs in high-risk "Infiltrating" HPV+ HNSCC. British Journal of Cancer, 2020, 123, 932-941.	6.4	7
1237	Blockade of programmed cell death protein 1 (PD-1) in S α zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. OncoImmunology, 2020, 9, 1738797.	4.6	32

#	ARTICLE	IF	CITATIONS
1238	Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?. Translational Oncology, 2020, 13, 100811.	3.7	46
1239	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. Frontiers in Immunology, 2020, 11, 1243.	4.8	30
1240	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. Neuro-Oncology Advances, 2020, 2, vdaa011.	0.7	22
1241	Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate. Scientific Reports, 2020, 10, 1852.	3.3	65
1242	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	1.6	3
1243	Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. Cancer Immunology, Immunotherapy, 2020, 69, 689-702.	4.2	16
1244	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. Immunology Letters, 2020, 221, 61-71.	2.5	12
1245	The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. Journal of Clinical Medicine, 2020, 9, 519.	2.4	26
1246	Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (United States), 2020, 99, e19059.	1.0	30
1247	Quantification of PD-L1 Expression with ¹⁸ F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2020, 61, 1455-1460.	5.0	54
1248	Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma. International Immunopharmacology, 2020, 82, 106245.	3.8	10
1249	The clinical potential of gene editing as a tool to engineer cell-based therapeutics. Clinical and Translational Medicine, 2020, 9, 15.	4.0	56
1250	Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1. Pathology Research and Practice, 2020, 216, 152847.	2.3	13
1251	The importance of FDG-PET/CT parameters for the assessment of the immune status in advanced HNSCC. Auris Nasus Larynx, 2020, 47, 658-667.	1.2	8
1252	Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathology Research and Practice, 2020, 216, 152852.	2.3	12
1253	VISTA: Coming of age as a multi-lineage immune checkpoint. Clinical and Experimental Immunology, 2020, 200, 120-130.	2.6	66
1254	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
1255	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. International Journal of Molecular Sciences, 2020, 21, 556.	4.1	21

#	ARTICLE	IF	CITATIONS
1256	Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. <i>Molecular Cancer</i> , 2020, 19, 19.	19.2	180
1257	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. <i>Journal of Cancer</i> , 2020, 11, 883-892.	2.5	5
1258	Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 643.	3.3	124
1259	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. <i>Immunity</i> , 2020, 52, 36-54.	14.3	127
1260	Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma. <i>Pediatric Surgery International</i> , 2020, 36, 137-143.	1.4	14
1261	Evaluating the role of FAMlly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020, 9, 1710389.	4.6	9
1262	Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. <i>Liver Cancer</i> , 2020, 9, 426-439.	7.7	26
1263	Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model. <i>Scientific Reports</i> , 2020, 10, 7078.	3.3	17
1264	The diverse roles of SPOP in prostate cancer and kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 339-350.	3.8	62
1265	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
1266	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337.	7.0	90
1267	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. <i>Nature Medicine</i> , 2020, 26, 566-576.	30.7	736
1268	HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC. <i>Frontiers in Oncology</i> , 2020, 10, 485.	2.8	21
1269	Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma. <i>Journal of Molecular Medicine</i> , 2020, 98, 805-818.	3.9	19
1270	Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2020, 9, 66.	5.3	16
1271	Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC. <i>Lung Cancer</i> , 2020, 144, 30-39.	2.0	23
1272	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. <i>Medicine (United States)</i> , 2020, 99, e19760.	1.0	34
1273	Biophysical and Immunological Characterization and <i>In Vivo</i> Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1298-1307.	4.1	8

#	ARTICLE	IF	CITATIONS
1274	PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer, 2020, 20, 277.	2.6	34
1275	<i>NFE2L2/KEAP1</i> Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy. Oncologist, 2020, 25, e955-e963.	3.7	39
1276	<p>Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date</p>. OncoTargets and Therapy, 2020, Volume 13, 3047-3059.	2.0	25
1277	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. Cancers, 2020, 12, 863.	3.7	18
1278	Primary mediastinal choriocarcinoma presenting as cutaneous metastasis with resistance to chemotherapy: case report and literature review. Journal of Cutaneous Pathology, 2021, 48, 81-85.	1.3	11
1279	Increased Expression of <sc>PD</sc>â€¹ and <sc>PDâ€¹L1</sc> in Patients With Laryngotracheal Stenosis. Laryngoscope, 2021, 131, 967-974.	2.0	18
1280	Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunology, Immunotherapy, 2021, 70, 61-73.	4.2	42
1281	Resistance mechanisms to immune checkpointsÂblockade by monoclonal antibody drugs in cancer immunotherapy: FocusÂon myeloma. Journal of Cellular Physiology, 2021, 236, 791-805.	4.1	13
1282	Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours. Neuroendocrinology, 2021, 111, 465-474.	2.5	15
1283	Biomarkers for predicting the outcome of various cancer immunotherapies. Critical Reviews in Oncology/Hematology, 2021, 157, 103161.	4.4	10
1284	Downregulation of Interferon- <i>Î³</i> Receptor Expression Endows Resistance to Antiâ€‘Programmed Death Protein 1 Therapy in Colorectal Cancer. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 21-28.	2.5	5
1285	Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines. Clinical and Translational Science, 2021, 14, 120-131.	3.1	3
1286	MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition. Modern Pathology, 2021, 34, 627-636.	5.5	13
1287	Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. Journal of Neuro-Oncology, 2021, 152, 15-25.	2.9	15
1288	Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. Clinical Genitourinary Cancer, 2021, 19, 53-59.e1.	1.9	6
1289	Determination of PD-1 expression in peripheral blood cells in patients with endometriosis. Gynecological Endocrinology, 2021, 37, 157-161.	1.7	5
1290	Oncolytic reovirus-mediated recruitment of early innate immune responses reverses immunotherapy resistance in prostate tumors. Molecular Therapy - Oncolytics, 2021, 20, 434-446.	4.4	17
1291	Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1/PD-L1 pathway and MAPK/ERK/JNK pathway for efficient treatment of colorectal cancer. Journal of Drug Targeting, 2021, 29, 454-465.	4.4	6

#	ARTICLE	IF	CITATIONS
1292	Expression of programmed cell death ligandâ€”1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large Bâ€”cell lymphoma of the central nervous system. Neuropathology, 2021, 41, 99-108.	1.2	8
1293	Advanced Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 111-128.	2.2	5
1294	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160.	4.4	26
1295	Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188463.	7.4	16
1296	PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology, 2021, 160, 781-796.	1.3	67
1297	Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma. Laryngoscope, 2021, 131, E1481-E1488.	2.0	15
1298	TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer. Translational Oncology, 2021, 14, 100918.	3.7	11
1299	PD-L1 status in breast cancer: Current view and perspectives. Seminars in Cancer Biology, 2021, 72, 146-154.	9.6	69
1300	Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. Theranostics, 2021, 11, 5955-5969.	10.0	23
1301	Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. Journal of Immunology Research, 2021, 2021, 1-18.	2.2	7
1302	Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients. Frontiers in Oncology, 2020, 10, 607349.	2.8	22
1303	Rethinking immune checkpoint blockade: â€”Beyond the T cellâ€”TM. , 2021, 9, e001460.		76
1304	Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity. , 2021, 9, e001595.		8
1305	Comprehensive Characterization of Tumor Microenvironment Differences in Cancer between Male and Female Patients. SSRN Electronic Journal, 0, , .	0.4	0
1306	Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110355.	1.3	45
1307	Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects. Drug Delivery, 2021, 28, 1849-1860.	5.7	7
1308	HSDL2 Acts as a Promoter in Pancreatic Cancer by Regulating Cell Proliferation and Lipid Metabolism. OncoTargets and Therapy, 2021, Volume 14, 435-444.	2.0	7
1309	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 334.	3.7	44

#	ARTICLE	IF	CITATIONS
1310	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021, 39, 829-835.	2.6	8
1311	Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC. <i>Theranostics</i> , 2021, 11, 7092-7109.	10.0	11
1312	Preclinical PET imaging with the novel human antibody ⁸⁹ Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues. , 2021, 9, e002025.		22
1313	MHC Class I Loss in Triple-negative Breast Cancer. <i>American Journal of Surgical Pathology</i> , 2021, 45, 701-707.	3.7	23
1314	Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas. <i>Scientific Reports</i> , 2021, 11, 1834.	3.3	27
1315	Immunophenotypic Differences in Tumor-Infiltrating Lymphocytes and Neovascularization Between Primary Cutaneous Melanoma With and Without Metastasis. <i>American Journal of Dermatopathology</i> , 2021, Publish Ahead of Print, 811-818.	0.6	0
1316	Interferon- γ /IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC). <i>Oncotarget</i> , 2021, 12, 2316-2317.	1.8	4
1317	Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. <i>Npj Genomic Medicine</i> , 2021, 6, 7.	3.8	41
1318	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. <i>Scientific Reports</i> , 2021, 11, 3667.	3.3	20
1319	Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 667.	3.7	27
1320	ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	107
1321	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. <i>Current Drug Targets</i> , 2021, 22, 162-170.	2.1	16
1322	Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients. <i>JAAD Case Reports</i> , 2021, 8, 28-33.	0.8	3
1323	Immune checkpoint inhibitors: Significant advancements in nonâ€‘small cell lung cancer treatment. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 769-780.	1.0	11
1324	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	27.6	646
1325	Targeting Innate Immunity in Cancer Therapy. <i>Vaccines</i> , 2021, 9, 138.	4.4	57
1326	Programmed cell deathâ€‘1/programmed cell deathâ€‘ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 400.	1.8	5
1327	What is the prospect of indoleamine 2,3-dioxygenase 1â€‘inhibition in cancer? Extrapolation from the past. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 60.	8.6	22

#	ARTICLE	IF	CITATIONS
1328	The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. ESMO Open, 2021, 6, 100008.	4.5	5
1329	ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer. Frontiers in Oncology, 2020, 10, 581733.	2.8	7
1330	Immunotherapy with 4-1BBL-Expressing iPS Cell-Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma. International Journal of Molecular Sciences, 2021, 22, 1958.	4.1	5
1331	A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 7.	5.4	29
1332	PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation. Cancers, 2021, 13, 555.	3.7	18
1333	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung Journal of Medical Sciences, 2021, 37, 448-458.	1.9	15
1334	Knowledge-based classification of fine-grained immune cell types in single-cell RNA-Seq data. Briefings in Bioinformatics, 2021, 22, .	6.5	11
1335	ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM. Siberian Journal of Oncology, 2021, 20, 115-122.	0.3	0
1336	Host response to immune checkpoint inhibitors contributes to tumor aggressiveness. , 2021, 9, e001996.		9
1337	Tumor immune microenvironment in brain metastases from gynecologic malignancies. Cancer Immunology, Immunotherapy, 2021, 70, 2951-2960.	4.2	9
1338	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 433-468.	1.7	7
1339	PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. Acta Pharmaceutica Sinica B, 2021, 11, 3120-3133.	12.0	16
1340	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nature Communications, 2021, 12, 1503.	12.8	45
1341	Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. Frontiers in Immunology, 2021, 12, 619209.	4.8	13
1342	A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas. Frontiers in Oncology, 2021, 11, 636057.	2.8	8
1343	A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). Molecular Medicine Reports, 2021, 23, .	2.4	16
1344	Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects. Cell Death and Disease, 2021, 12, 299.	6.3	25
1345	Discipline in Stages: Regulating CD8+ Resident Memory T Cells. Frontiers in Immunology, 2020, 11, 624199.	4.8	7

#	ARTICLE	IF	CITATIONS
1346	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 1402.	12.8	85
1347	The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. <i>Frontiers in Oncology</i> , 2021, 11, 573547.	2.8	11
1348	Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance. <i>Biomedicines</i> , 2021, 9, 304.	3.2	16
1349	POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 640018.	2.8	24
1350	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 617335.	2.8	49
1351	A Supramolecular “Trident” for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2100729.	14.9	29
1353	PD-1/PD-L1 Expression Levels and Prognostic Significance in Chronic Lymphocytic Leukemia. <i>Acibadem Universitesi Saglik Bilimleri Dergisi</i> , 2021, 12, .	0.1	0
1354	Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by pembrolizumab: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 2281-2288.	0.8	6
1355	Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. <i>Biomedicines</i> , 2021, 9, 373.	3.2	55
1356	Advances in immunotherapy for pancreatic ductal adenocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 419-430.	2.6	9
1357	The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 665147.	4.8	11
1358	Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer. <i>Cells</i> , 2021, 10, 872.	4.1	2
1359	Immune-related biomarkers in triple-negative breast cancer. <i>Breast Cancer</i> , 2021, 28, 792-805.	2.9	24
1360	Mucinous Colorectal Cancer is Associated With Expression of the TIM-3 Immune Checkpoint Independently of Microsatellite Instability (MSI) Status. <i>Annals of Surgical Oncology</i> , 2021, 28, 7999-8006.	1.5	3
1361	Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. , 2021, 9, e001752.		34
1362	Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. <i>Future Oncology</i> , 2021, 17, 1553-1569.	2.4	9
1363	Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. <i>European Journal of Pharmacology</i> , 2021, 897, 173960.	3.5	5
1365	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. <i>Brain</i> , 2021, 144, 1046-1066.	7.6	24

#	ARTICLE	IF	CITATIONS
1366	Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1639.	3.7	13
1367	miRNAs as novel immunoregulators in cancer. <i>Seminars in Cell and Developmental Biology</i> , 2022, 124, 3-14.	5.0	11
1368	Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. <i>Cancers</i> , 2021, 13, 1682.	3.7	16
1369	Addressing resistance to immune checkpoint inhibitor therapy:Âan urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	2.4	17
1370	Concomitant Expression of Inhibitory Molecules for T cell Activation Predicts Poor Survival in Patients with Esophageal Squamous Cell Carcinoma. <i>Current Cancer Drug Targets</i> , 2021, 21, 244-253.	1.6	2
1372	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	1.2	38
1373	Inpatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 667-673.	1.2	11
1374	Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1083-1097.	12.0	23
1375	Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma. <i>Journal of Genetics and Genomics</i> , 2021, 48, 361-368.	3.9	3
1376	Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents. <i>Journal of Personalized Medicine</i> , 2021, 11, 460.	2.5	5
1377	Immuneârelated adverse events predict responses to <sc>PD</sc>â1 blockade immunotherapy in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2021, 149, 959-966.	5.1	15
1378	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	6.9	5
1379	Interferon regulatory factor 1 (IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). <i>Cancer Letters</i> , 2021, 506, 95-106.	7.2	36
1380	A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 809-809.	1.7	9
1381	Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. <i>Cell Discovery</i> , 2021, 7, 36.	6.7	109
1382	Microenvironmental regulation of tumour immunity and response to immunotherapy. <i>Journal of Pathology</i> , 2021, 254, 374-383.	4.5	17
1383	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. <i>Cancers</i> , 2021, 13, 2630.	3.7	3
1384	Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression. <i>Cell Communication and Signaling</i> , 2021, 19, 50.	6.5	14

#	ARTICLE	IF	CITATIONS
1385	Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. <i>Cancers</i> , 2021, 13, 2632.	3.7	14
1387	PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 2305-2317.	1.0	3
1388	In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy. <i>Chinese Chemical Letters</i> , 2021, 32, 1770-1774.	9.0	41
1389	Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	1
1390	The genetic and epigenetic basis of distinct melanoma types. <i>Journal of Dermatology</i> , 2021, 48, 925-939.	1.2	6
1391	Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. <i>Communications Biology</i> , 2021, 4, 638.	4.4	12
1392	Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. <i>Cancer Cell International</i> , 2021, 21, 262.	4.1	31
1393	Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 827-835.	4.1	3
1394	Explant Modeling of the Immune Environment of Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 611365.	2.8	6
1395	Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 2509-2522.	2.8	13
1396	Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal. <i>Cancers</i> , 2021, 13, 3170.	3.7	6
1397	Inverse correlation between PD-L1 expression and LGR5 expression in tumor budding of stage II/III colorectal cancer. <i>Annals of Diagnostic Pathology</i> , 2021, 52, 151739.	1.3	6
1398	Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer. <i>Cancer Medicine</i> , 2021, 10, 5375-5391.	2.8	6
1399	Identification of gastric cancer subtypes based on pathway clustering. <i>Npj Precision Oncology</i> , 2021, 5, 46.	5.4	28
1400	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021, 2, 207-222.	1.2	0
1401	PD-1 and PD-L2: Do they have prognostic value in lymphomas?. <i>Cumhuriyet Medical Journal</i> , 0, , .	0.1	0
1402	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 625-644.	27.6	148
1403	Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. <i>Biomedicines</i> , 2021, 9, 632.	3.2	30

#	ARTICLE	IF	CITATIONS
1404	The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 689132.	4.8	55
1405	The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2539-2550.	2.8	6
1406	Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , 2021, 10, 1651.	4.1	13
1407	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. <i>Hepatology Communications</i> , 2022, 6, 178-193.	4.3	16
1408	Programmed Cell Death Ligand 1 Expression Level and Prognostic Significance in Acute Myeloid Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , 1.	0.6	0
1409	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
1410	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	10
1411	Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. <i>Translational Oncology</i> , 2021, 14, 101102.	3.7	8
1412	Review of applications of CRISPR-Cas9 gene-editing technology in cancer research. <i>Biological Procedures Online</i> , 2021, 23, 14.	2.9	18
1413	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3077-3088.	3.5	5
1414	The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 670391.	4.8	48
1415	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. <i>Scientific Reports</i> , 2021, 11, 15312.	3.3	15
1416	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651.	2.5	28
1418	A review on the advances and challenges of immunotherapy for head and neck cancer. <i>Cancer Cell International</i> , 2021, 21, 406.	4.1	30
1419	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 891-903.	13.2	147
1420	The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 4301-4310.	1.4	6
1421	Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo. <i>BioMed Research International</i> , 2021, 2021, 1-9.	1.9	4
1422	Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1008-1046.	6.4	28

#	ARTICLE	IF	CITATIONS
1423	Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. , 2021, 9, e002197.		44
1424	Immune Checkpoint Inhibitors in Human Glioma Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 679425.	4.8	76
1425	Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 807-818.	4.2	8
1426	Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4217-4228.	3.5	20
1427	A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. <i>BMC Cancer</i> , 2021, 21, 901.	2.6	20
1428	Prognostic Value and Immunological Characteristics of a Novel RNA Binding Protein Signature in Cutaneous Melanoma. <i>Frontiers in Genetics</i> , 2021, 12, 723796.	2.3	5
1429	Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates. <i>Journal of Translational Medicine</i> , 2021, 19, 371.	4.4	9
1430	Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic. <i>Frontiers in Oncology</i> , 2021, 11, 698425.	2.8	14
1431	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
1432	The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. <i>Seminars in Cancer Biology</i> , 2021, 73, 356-376.	9.6	32
1433	Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance. <i>Cancers</i> , 2021, 13, 4124.	3.7	17
1434	Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by <i>FANCM</i> Mutations. <i>JCO Precision Oncology</i> , 2021, 5, 1443-1448.	3.0	5
1435	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	4
1436	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2647-2655.	1.6	94
1437	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	3.2	46
1438	Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens. <i>Pathology</i> , 2021, 53, 586-594.	0.6	10
1439	Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell cold solid tumors. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	40
1440	Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer—May Cold Tumors Simply Be Too Hot?. <i>Frontiers in Immunology</i> , 2021, 12, 716342.	4.8	11

#	ARTICLE	IF	CITATIONS
1441	APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma. <i>International Immunopharmacology</i> , 2021, 97, 107675.	3.8	11
1442	Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients. <i>Cancers</i> , 2021, 13, 3896.	3.7	7
1443	Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2078-2090.	1.1	29
1444	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
1445	Chemokine CxCL12 motif ligand 21 synergized with programmed death-1 ligand 1 blockade restrains tumor growth. <i>Cancer Science</i> , 2021, 112, 4457-4469.	3.9	10
1446	Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 744571.	4.8	8
1447	Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	8
1448	Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. <i>Frontiers in Oncology</i> , 2021, 11, 753788.	2.8	4
1449	NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. <i>Cancers</i> , 2021, 13, 4543.	3.7	14
1450	Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing. , 0, , .		10
1451	Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 582664.	2.8	11
1452	The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4876.	3.7	27
1453	Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. <i>Cancers</i> , 2021, 13, 4919.	3.7	5
1454	Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 653319.	4.8	7
1455	Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review). <i>Oncology Letters</i> , 2021, 22, 809.	1.8	7
1456	Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. <i>Modern Pathology</i> , 2022, 35, 142-151.	5.5	7
1457	The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1129-1137.	4.2	9
1458	Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?. <i>Pathology Research and Practice</i> , 2021, 226, 153606.	2.3	7

#	ARTICLE	IF	CITATIONS
1459	Immunotherapy for Head and Neck Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 1021-1037.	2.2	8
1460	A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. Cancer Letters, 2021, 522, 184-197.	7.2	17
1461	Nucleic acid biomarker technology for cancer immunotherapy. , 2022, , 331-356.		0
1462	Investigation of an Alternative Marker for Hypermutability Evaluation in Different Tumors. Genes, 2021, 12, 197.	2.4	4
1463	An experimental model of anti-PD-1 resistance exhibits activation of TGFβ and Notch pathways and is sensitive to local mRNA immunotherapy. OncoImmunology, 2021, 10, 1881268.	4.6	18
1464	Immune Checkpoint Inhibitors as an Armor for Targeted Immunotherapy of Colorectal Cancer. , 2021, , 309-326.		0
1465	Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobe. Theranostics, 2021, 11, 7360-7378.	10.0	18
1466	MXD3 as an onco-immunological biomarker encompassing the tumor microenvironment, disease staging, prognoses, and therapeutic responses in multiple cancer types. Computational and Structural Biotechnology Journal, 2021, 19, 4970-4983.	4.1	25
1467	Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma. Anticancer Research, 2021, 41, 101-111.	1.1	7
1468	Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis. Technology in Cancer Research and Treatment, 2021, 20, 153303382110194.	1.9	8
1469	Status of Immune Oncology: Challenges and Opportunities. Methods in Molecular Biology, 2020, 2055, 3-21.	0.9	6
1470	The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. Recent Results in Cancer Research, 2020, 214, 169-187.	1.8	7
1471	Immuno-oncology of Dormant Tumours. Cancer Drug Discovery and Development, 2017, , 51-60.	0.4	1
1472	Antibody Therapies in Cancer. Advances in Experimental Medicine and Biology, 2016, 909, 1-67.	1.6	8
1473	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1248, 143-166.	1.6	3
1474	Double immune checkpoint blockade in advanced NSCLC. Critical Reviews in Oncology/Hematology, 2020, 152, 102980.	4.4	12
1475	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. British Journal of Cancer, 2018, 119, 80-88.	6.4	74
1476	Analysis of the Molecular Signature of Breast Implant-Associated Anaplastic Large Cell Lymphoma in an Asian Patient. Aesthetic Surgery Journal, 2021, 41, NP214-NP222.	1.6	9

#	ARTICLE	IF	CITATIONS
1477	PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 748-754.	1.2	7
1478	Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2020, Publish Ahead of Print, 201-208.	1.2	6
1479	PD-L1 Interpretation in Cervical Carcinomas: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. International Journal of Gynecological Pathology, 2021, 40, 1-4.	1.4	4
1480	PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Annals of Surgery, 2019, 269, 471-478.	4.2	135
1486	Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. Journal of Immunology Research, 2020, 2020, 1-15.	2.2	11
1487	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight, 2019, 4, .	5.0	345
1488	Multiparametric profiling of nonâ€‘small-cell lung cancers reveals distinct immunophenotypes. JCI Insight, 2016, 1, e89014.	5.0	110
1489	Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. Journal of Clinical Investigation, 2020, 130, 4266-4281.	8.2	27
1490	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockadeâ€‘mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 805-815.	8.2	423
1491	Analysis of PDL1 expression and T cells infiltration in 1014 gastric cancer patients.. Journal of Clinical Oncology, 2017, 35, 50-50.	1.6	1
1492	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Medicine, 2016, 13, e1002196.	8.4	21
1493	Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM). PLoS ONE, 2015, 10, e0121071.	2.5	185
1494	The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. PLoS ONE, 2015, 10, e0138726.	2.5	24
1495	Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma. PLoS ONE, 2016, 11, e0157176.	2.5	92
1496	PD-L1 Status in Refractory Lymphomas. PLoS ONE, 2016, 11, e0166266.	2.5	47
1497	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e132-e139.	3.8	11
1498	Biomarkers for Checkpoint Inhibition. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 205-209.	3.8	12
1499	Immunotherapy failure in adrenocortical cancer: where next?. Endocrine Connections, 2018, 7, E5-E8.	1.9	39

#	ARTICLE	IF	CITATIONS
1500	Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. <i>Endocrine-Related Cancer</i> , 2019, 26, 293-301.	3.1	62
1501	Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142.		31
1502	Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma. <i>Oncologist</i> , 2020, 25, 438-446.	3.7	56
1503	Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. <i>Bosnian Journal of Basic Medical Sciences</i> , 2019, 19, 227-233.	1.0	76
1504	Modern approaches to kidney cancer immunotherapy. <i>Onkourologiya</i> , 2018, 14, 54-67.	0.3	15
1505	Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2019, 19, 1-11.	1.1	4
1506	Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine. <i>Advances in Modern Oncology Research</i> , 2016, 2, 18.	0.1	5
1507	CTLA-4 immunotherapy exposes differences in immune response along with different tumor progression in colorectal cancer. <i>Aging</i> , 2020, 12, 15656-15669.	3.1	6
1508	Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 47252-47264.	1.8	79
1509	PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. <i>Oncotarget</i> , 2016, 7, 59976-59986.	1.8	56
1510	Prognostic value of <i>PDL1</i> expression in pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 71198-71210.	1.8	81
1511	Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. <i>Oncotarget</i> , 2016, 7, 64318-64329.	1.8	40
1512	Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma. <i>Oncotarget</i> , 2016, 7, 69749-69759.	1.8	20
1513	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. <i>Oncotarget</i> , 2016, 7, 76891-76901.	1.8	9
1514	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	1.8	93
1515	Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 9354-9365.	1.8	32
1516	Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. <i>Oncotarget</i> , 2017, 8, 20394-20409.	1.8	30
1517	Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. <i>Oncotarget</i> , 2017, 8, 14759-14769.	1.8	39

#	ARTICLE	IF	CITATIONS
1518	Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 30175-30189.	1.8	69
1519	The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. <i>Oncotarget</i> , 2017, 8, 26789-26801.	1.8	64
1520	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. <i>Oncotarget</i> , 2017, 8, 54722-54734.	1.8	39
1521	Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 59901-59914.	1.8	64
1522	PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment. <i>Oncotarget</i> , 2017, 8, 59677-59689.	1.8	7
1523	Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment. <i>Oncotarget</i> , 2017, 8, 85526-85536.	1.8	21
1524	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA <i>in situ</i> hybridization. <i>Oncotarget</i> , 2017, 8, 87234-87243.	1.8	17
1525	Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. <i>Oncotarget</i> , 2017, 8, 87317-87328.	1.8	30
1526	PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. <i>Oncotarget</i> , 2017, 8, 101535-101544.	1.8	42
1527	Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 103117-103128.	1.8	84
1528	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. <i>Oncotarget</i> , 2017, 8, 111836-111846.	1.8	44
1529	Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. <i>Oncotarget</i> , 2018, 9, 4375-4384.	1.8	26
1530	The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. <i>Oncotarget</i> , 2018, 9, 6201-6212.	1.8	33
1531	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. <i>Oncotarget</i> , 2018, 9, 5652-5664.	1.8	105
1532	T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. <i>Oncotarget</i> , 2018, 9, 6536-6549.	1.8	37
1533	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	1.8	29
1534	PD-L1 expression in medulloblastoma: an evaluation by subgroup. <i>Oncotarget</i> , 2018, 9, 19177-19191.	1.8	45
1535	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. <i>Oncotarget</i> , 2018, 9, 30465-30471.	1.8	26

#	ARTICLE	IF	CITATIONS
1536	Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles. <i>Oncotarget</i> , 2018, 9, 34229-34239.	1.8	2
1537	STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNF α mediated immune responses in a model of NSCLC. <i>Oncotarget</i> , 2018, 9, 37157-37172.	1.8	10
1538	Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. <i>Oncotarget</i> , 2015, 6, 9612-9626.	1.8	166
1539	Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. <i>Oncotarget</i> , 2015, 6, 11139-11149.	1.8	89
1540	Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. <i>Oncotarget</i> , 2015, 6, 19819-19825.	1.8	80
1541	Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 26483-26493.	1.8	118
1542	Vesicular stomatitis virus expressing interferon- β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33165-33177.	1.8	87
1543	Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. <i>Oncotarget</i> , 2016, 7, 8944-8955.	1.8	60
1544	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	1.8	134
1545	Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. <i>Oncotarget</i> , 2016, 7, 18508-18520.	1.8	75
1546	The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutic drugs may finally work through immune response. <i>Oncotarget</i> , 2016, 7, 29794-29803.	1.8	48
1547	Using lymph node swelling as a potential biomarker for successful vaccination. <i>Oncotarget</i> , 2016, 7, 35655-35669.	1.8	11
1548	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. <i>Annals of Translational Medicine</i> , 2016, 4, 267-267.	1.7	17
1549	Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4—a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2017, 5, 467-467.	1.7	12
1550	Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 31-31.	1.2	12
1551	Advances and challenges in immunotherapy of small cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 115-128.	2.2	19
1552	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. <i>Current Medicinal Chemistry</i> , 2020, 27, 2402-2448.	2.4	12
1553	Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2020, 23, 687-698.	1.1	7

#	ARTICLE	IF	CITATIONS
1554	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 100-112.	1.6	16
1555	Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 222-228.	1.7	4
1556	PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Anticancer Research, 2017, 37, 1417-1424.	1.1	51
1557	Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer. Anticancer Research, 2017, 37, 5087-5094.	1.1	15
1558	Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. , 2017, 37, 5655-5666.		26
1559	Immunotherapy and potential molecular targets for the treatment of pituitary adenomas resistant to standard therapy: a critical review of potential therapeutic targets and current developments. Journal of Neurosurgical Sciences, 2020, 64, 71-83.	0.6	7
1560	Updates to Clinical Information on Anticancer Immunotherapy. Korean Journal of Clinical Pharmacy, 2018, 28, 65-75.	0.3	3
1561	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. Cancers, 2020, 12, 2835.	3.7	8
1562	Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. International Journal of Molecular Sciences, 2020, 21, 7139.	4.1	33
1563	Progress in systemic therapy of advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 6582.	3.3	43
1564	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World Journal of Gastroenterology, 2018, 24, 2686-2697.	3.3	23
1567	Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors. Oncology Letters, 2020, 19, 2817-2824.	1.8	13
1568	Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review). Oncology Letters, 2020, 20, 45.	1.8	12
1569	Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncology Reports, 2020, 44, 424-437.	2.6	18
1570	Impact of the immune system and immunotherapy in colorectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 208-23.	1.4	142
1571	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 2014, 3, 403-5.	2.8	21
1572	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Translational Lung Cancer Research, 2015, 4, 728-42.	2.8	48
1573	Checkpoint inhibitors in the treatment of cutaneous malignant melanoma. Chinese Clinical Oncology, 2014, 3, 30.	1.2	6

#	ARTICLE	IF	CITATIONS
1574	Predictive factors for immunotherapy in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 208.	1.7	27
1575	Perspectives on the clinical development of immunotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 253.	1.6	13
1576	Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance. <i>Indian Journal of Ophthalmology</i> , 2019, 67, 1983.	1.1	10
1577	Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. <i>Journal of Pathology and Translational Medicine</i> , 2015, 49, 355-363.	1.1	41
1578	Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. <i>Translational Oncogenomics</i> , 2015, Suppl. 1, 1-11.	1.7	19
1579	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 1112-1119.	3.0	10
1580	Assays for predicting and monitoring responses to lung cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 87-95.	3.0	35
1581	Tumor immune microenvironment characterization and response to anti-PD-1 therapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 74-8.	3.0	60
1582	Advances in immunotherapy for treatment of lung cancer. <i>Cancer Biology and Medicine</i> , 2015, 12, 209-22.	3.0	50
1583	Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. <i>Cancer Biology and Medicine</i> , 2015, 12, 201-8.	3.0	67
1584	Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. <i>ELife</i> , 2020, 9, .	6.0	81
1585	The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2021, 12, 726448.	3.5	11
1586	The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Molecular Medicine</i> , 2021, 27, 126.	4.4	9
1587	Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab. <i>Clinical and Translational Oncology</i> , 2022, 24, 568-577.	2.4	6
1588	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760211.	3.7	9
1589	Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.9	3
1590	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2021, 9, 1465-1475.	3.4	8
1591	Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. <i>International Journal of Hyperthermia</i> , 2021, 38, 1519-1528.	2.5	21

#	ARTICLE	IF	CITATIONS
1592	PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis. Australasian Journal of Dermatology, 2021, , .	0.7	3
1594	Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
1595	Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN- γ signaling and tumor-infiltrating lymphocytes. Journal of Hematology and Oncology, 2021, 14, 160.	17.0	37
1596	Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression. International Immunopharmacology, 2021, 101, 108199.	3.8	5
1597	Recent Updates in Cancer Immunotherapy. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2015, 58, 449.	0.2	1
1598	Immune Microenvironment and its Therapeutic Implication in Non-Small Cell Lung Carcinoma: Literature Review. Journal of Clinical & Cellular Immunology, 2015, 05, .	1.5	0
1599	Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. , 2015, , 85-101.		0
1600	Managing Advanced Melanoma: Targeting the PD-1 Pathway with Pembrolizumab. Cancer Research Frontiers, 2015, 1, 127-137.	0.2	0
1601	Improving of Antitumor Immunity and Therapeutic Efficacy of Cancer Vaccines and Adoptive Immunotherapies Using Monoclonal Antibodies. MOJ Immunology, 2015, 2, .	11.0	0
1602	Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. Giornale Di Chirurgia, 2017, 37, 225-235.	0.2	6
1603	Tumor Immunology and Immunotherapy in Cancer Patients. , 2016, , 425-442.		2
1604	Determination of Background Ionizing Radiations in Selected Buildings in Nairobi County, Kenya. Journal of Nuclear Medicine & Radiation Therapy, 2016, 07, .	0.2	0
1605	Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer. Forum of Clinical Oncology, 2016, 7, 4-16.	0.2	0
1606	Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches. Current Pharmaceutical Design, 2016, 22, 2431-2438.	1.9	8
1607	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.4	3
1609	æ,³æ\$é»'è%²è...«ã@æ²»ç™,1/4šè†â•ãĒă,“ă...ç—«ç™,æ³•ã•ã•@â•èf1/2æ€\$. Skin Cancer, 2017, 32, 106-111.	0.0	0
1610	Immunotherapy for Renal Cell Cancer (RCC). , 2017, , 295-317.		0
1611	Combinational Immunotherapy of Gastric Cancer. , 2017, , 163-175.		0

#	ARTICLE	IF	CITATIONS
1612	Dynamic changes in PD-1 and PD-L1 expressions in cases with Hodgkin Lymphoma. Clinical Research and Trials, 2018, 4, .	0.1	1
1613	Analytical validation of a novel multi-analyte plasma test for lung nodule characterization. Biomedical Research and Reviews, 2018, 2, .	0.1	2
1616	ULTRASOUND TUMOR ABLATION: IMMUNE EFFECTS AND PERSPECTIVES OF INTEGRATION IN THE MODERN TREATMENT OF ADVANCED CANCER. Malignant Tumours, 2018, 8, 31-42.	0.5	0
1618	Personalized Cancer Immunotherapy: Today's Challenge and Tomorrow's Promise. Journal of Immunotherapy and Precision Oncology, 2018, 1, 56-67.	1.4	4
1619	Melanoma Vaccines. , 2019, , 1-23.		0
1620	Correlation of programmed death ligand 1 expression with overall survival, clinical, and pathological features in patients with malignant plural mesothelioma. Egyptian Journal of Pathology, 2019, 39, 317.	0.0	0
1621	Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159.		3
1622	Desperate times, desperate measures: Low-dose nivolumab-induced remission in relapsed NSCLC. Cancer Research Statistics and Treatment, 2019, 2, 266.	0.6	0
1623	Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective. Methods in Molecular Biology, 2020, 2055, 701-716.	0.9	2
1624	Lung Carcinoma Presenting as a Superior Vena Cava Syndrome, Burnt and Twice Reborn as Adrenal and Facial Tumors. Cureus, 2019, 11, e5746.	0.5	1
1625	Regional Gene Therapy for Cancer. , 2020, , 55-71.		0
1626	Immunotherapy in Pediatric Solid Tumors. Clinical Pediatric Hematology-Oncology, 2020, 27, 22-31.	0.2	1
1628	Î2-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas. International Journal of Gynecological Cancer, 2020, 30, 993-999.	2.5	6
1629	Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review. American Journal of Dermatopathology, 2021, 43, 321-330.	0.6	2
1630	PD-L1 and CD8-Tumor-Infiltrating Lymphocytes Expression in Laryngeal Squamous Cell Carcinoma. ARS Medica Tomitana, 2020, 26, 137-144.	0.1	0
1631	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
1632	Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer. The Journal of Breast Health, 2020, 16, 276-281.	1.0	5
1633	Cemiplimab in advanced cutaneous squamous cell carcinoma. Dermatologic Therapy, 2021, 34, e15184.	1.7	4

#	ARTICLE	IF	CITATIONS
1634	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. <i>Cancers</i> , 2021, 13, 5415.	3.7	13
1635	Tumor Microenvironment Profiles Reveal Distinct Therapy-Oriented Proteogenomic Characteristics in Colorectal Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 757378.	4.1	6
1637	Lentinan, a Shiitake Mushroom β -Glucan, Downregulates the Enhanced PD-L1 Expression Induced by Platinum Compounds in Gastric Cancer Cells -. <i>Journal of Analytical Oncology</i> , 0, 9, 1-10.	0.1	2
1638	Models for Monocytic Cells in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1224, 87-115.	1.6	8
1639	Acral Lentiginous Melanoma. , 2020, , 897-924.		0
1640	Melanoma Vaccines. , 2020, , 1243-1265.		0
1641	Is Precision Oncology Beneficial for Glioblastomas ?. <i>Japanese Journal of Neurosurgery</i> , 2020, 29, 181-187.	0.0	0
1642	Cancer Imaging with Radiolabeled Monoclonal Antibodies. , 2020, , 739-760.		5
1643	Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience. <i>World Journal of Oncology</i> , 2020, 11, 150-157.	1.5	3
1646	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2021, 5, 1625-1638.	3.0	10
1647	Progress in research of tumor infiltrating lymphocytes in pancreatic cancer. <i>World Chinese Journal of Digestology</i> , 2021, 29, 1207-1214.	0.1	0
1648	Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients. <i>Anticancer Research</i> , 2021, 41, 5739-5747.	1.1	4
1649	Advances in Pancreatic Ductal Adenocarcinoma Treatment. <i>Cancers</i> , 2021, 13, 5510.	3.7	28
1650	Radiotherapy and immunotherapy: open questions and future strategies. <i>Trends in Cancer</i> , 2022, 8, 9-20.	7.4	49
1651	Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. <i>ELife</i> , 2021, 10, .	6.0	8
1652	SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis. <i>Cancer Research</i> , 2021, 81, 6131-6141.	0.9	31
1653	The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer. <i>Translational Cancer Research</i> , 2020, 9, 4111-4120.	1.0	5
1655	Novel Therapies in Development for Metastatic Colorectal Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, S2-7.	0.7	2

#	ARTICLE	IF	CITATIONS
1656	Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. American Journal of Translational Research (discontinued), 2016, 8, 3274-87.	0.0	35
1658	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, 498-509.	0.4	6
1660	Immune reaction by cytoreductive prostatectomy. American Journal of Clinical and Experimental Urology, 2019, 7, 64-79.	0.4	2
1662	Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. International Journal of Clinical and Experimental Pathology, 2018, 11, 304-313.	0.5	7
1663	CD163/CD68 tumor-associated macrophages in angiosarcoma with lymphedema. International Journal of Clinical and Experimental Pathology, 2018, 11, 2106-2111.	0.5	0
1664	Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. American Journal of Cancer Research, 2020, 10, 1085-1102.	1.4	2
1665	Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry. Annals of Clinical and Laboratory Science, 2020, 50, 213-218.	0.2	1
1666	Glycosylation of Siglec15 promotes immunoescape and tumor growth. American Journal of Cancer Research, 2021, 11, 2291-2302.	1.4	0
1667	Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma. Dermatology Practical and Conceptual, 2021, 11, e2021169S.	0.9	9
1668	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 12330.	4.1	16
1669	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. Cells, 2021, 10, 3166.	4.1	20
1670	Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Archives of Dermatological Research, 2021, , 1.	1.9	1
1671	Pan-cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors. Cancer Medicine, 2021, , .	2.8	10
1673	Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India. Journal of Laboratory Physicians, 0, , .	1.1	1
1674	The role of the immunoescape in colorectal cancer liver metastasis. PLoS ONE, 2021, 16, e0259940.	2.5	5
1675	Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients. Frontiers in Oncology, 2021, 11, 798385.	2.8	11
1676	Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis. Future Oncology, 2022, 18, 883-896.	2.4	3
1677	Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo. Frontiers in Pharmacology, 2021, 12, 774231.	3.5	9

#	ARTICLE	IF	CITATIONS
1678	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinicâ€“Pathologic Correlations. Cells, 2021, 10, 3165.	4.1	9
1679	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). International Journal of Molecular Sciences, 2021, 22, 12297.	4.1	10
1680	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2022, 27, 59-71.	2.2	19
1681	Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 987-1005.	3.4	8
1682	BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment. Cancer Research, 2022, 82, 264-277.	0.9	8
1683	Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. , 2021, 9, e003195.		3
1684	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1. International Journal of Molecular Sciences, 2021, 22, 12314.	4.1	6
1685	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature Communications, 2021, 12, 7005.	12.8	66
1686	Therapie des Nierenzellkarzinoms: Das Spektrum erweitert sich. , 0, , .		0
1687	Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma. Translational Cancer Research, 2022, 11, 193-205.	1.0	10
1688	Association between clinicopathological features and prognosis significance of PD-L1 expression in small cell lung cancer patients: a systemic review and meta-analysis. Translational Cancer Research, 2020, 9, 5508-5516.	1.0	2
1689	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
1690	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. Biomedicines, 2022, 10, 236.	3.2	13
1691	Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International, 2022, 22, 2.	4.1	83
1692	Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy. Future Medicinal Chemistry, 2022, 14, 97-113.	2.3	10
1693	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. OncoImmunology, 2022, 11, 1993042.	4.6	16
1694	DNA damage response inhibitor and anti-PD-L1 therapy for prostate cancer: Development of predictive biomarkers. Engineering, 2022, , .	6.7	0
1695	Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma. Frontiers in Immunology, 2022, 13, 818411.	4.8	1

#	ARTICLE	IF	CITATIONS
1696	Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 749-761.	3.4	3
1697	Immune microenvironment in patients with mismatch repair proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. <i>Molecular Oncology</i> , 2022, 16, 2260-2273.	4.6	5
1698	Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1213-1223.	1.7	0
1699	Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6. <i>International Journal of Hyperthermia</i> , 2022, 39, 278-286.	2.5	19
1700	Current therapy and development of therapeutic agents for lung cancer. , 2022, 1, 100015.		8
1701	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. <i>Porto Biomedical Journal</i> , 2022, 7, e162.	1.0	3
1702	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1312.	2.5	6
1703	PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. <i>American Journal of Cancer Research</i> , 2021, 11, 5006-5015.	1.4	0
1704	Research progress in immunotherapy of NSCLC with EGFR sensitive mutations. <i>Oncology Research</i> , 2022, , .	1.5	0
1705	Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma. <i>Journal of Applied Oral Science</i> , 2022, 30, e20210344.	1.8	1
1707	Biomarkers of response to PD-1 pathway blockade. <i>British Journal of Cancer</i> , 2022, 126, 1663-1675.	6.4	52
1708	Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment. <i>Pathology and Oncology Research</i> , 2022, 28, 1610196.	1.9	1
1709	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.7	1
1710	Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective. <i>Current Treatment Options in Oncology</i> , 2022, 23, 268-294.	3.0	8
1711	Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence. <i>Brain Sciences</i> , 2022, 12, 266.	2.3	0
1712	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 331-338.	6.7	16
1713	A Potential Diagnostic and Prognostic Biomarker TMEM176B and Its Relationship With Immune Infiltration in Skin Cutaneous Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 859958.	3.7	5
1714	Fluence rate differences in photodynamic therapy efficacy and activation of immune checkpoints of murine colorectal cancer. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
1715	Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. <i>Molecular Oncology</i> , 2022, 16, 2153-2173.	4.6	13
1716	CMTM6 as a master regulator of PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2325-2340.	4.2	7
1717	PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. <i>Cell Reports</i> , 2022, 38, 110582.	6.4	24
1718	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. <i>Cancers</i> , 2022, 14, 1367.	3.7	10
1719	Colorectal liver metastasis: molecular mechanism and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 70.	17.1	88
1720	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 40-50.	1.1	0
1721	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. , 2022, 10, e003420.		11
1722	Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. <i>Biomedicine</i> , 2022, 10, 650.	3.2	24
1723	Evaluation of HSP-27, BAP1, BRAF V600E, CCR7, and PD-L1 expression in uveal melanoma on enucleated eyes and metastatic liver tumors. <i>International Journal of Biological Markers</i> , 2022, 37, 200-209.	1.8	3
1724	Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma. <i>Current Otorhinolaryngology Reports</i> , 0, , 1.	0.5	0
1725	Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents. <i>Healthcare (Switzerland)</i> , 2022, 10, 694.	2.0	4
1726	Impact of HPV status on immune responses in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 127, 105774.	1.5	11
1727	Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4044.	4.1	9
1728	A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies. <i>Frontiers in Immunology</i> , 2022, 13, 864423.	4.8	2
1729	A deep learning-based computational prediction model for characterizing cellular biomarker distribution in tumor microenvironment. , 2022, , .		0
1730	Networks of CD8+ T Cell Response Activation in Melanoma and Vitiligo. <i>Frontiers in Immunology</i> , 2022, 13, 866703.	4.8	11
1731	Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112923.	5.6	7
1732	A highly branched 1,6-d-glucan facilitates antitumor immunity by reducing cancer cell CXCL5 expression. <i>International Journal of Biological Macromolecules</i> , 2022, 209, 166-179.	7.5	3

#	ARTICLE	IF	CITATIONS
1733	Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis. Healthcare (Switzerland), 2022, 10, 75.	2.0	5
1734	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10
1735	Central Role of the Antigen-Presentation and Interferon- γ Pathways in Resistance to Immune Checkpoint Blockade. Annual Review of Cancer Biology, 2022, 6, 85-102.	4.5	15
1736	Reverse Translating Molecular Determinants of Anti-“Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models. Molecular Cancer Therapeutics, 2022, 21, 427-439.	4.1	10
1737	PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China. Frontiers in Oncology, 2021, 11, 745493.	2.8	2
1738	Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature. BMC Cancer, 2021, 21, 1324.	2.6	8
1739	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	46.4	201
1740	Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma. Oncology, 2022, 100, 39-47.	1.9	8
1741	Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. Frontiers in Oncology, 2021, 11, 734354.	2.8	17
1742	A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy. Cancers, 2022, 14, 203.	3.7	7
1743	GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response. Frontiers in Oncology, 2021, 11, 733533.	2.8	4
1744	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. Cancer Medicine, 2022, 11, 880-887.	2.8	5
1745	Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8+ T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma. International Journal of General Medicine, 2022, Volume 15, 4209-4220.	1.8	3
1747	Molecular classification of hormone-“sensitive and castration-“resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. Prostate, 2022, 82, 993-1002.	2.3	2
1748	Tumor Vascular Remodeling Affects Molecular Dissemination to Lymph Node and Systemic Leukocytes. Tissue Engineering - Part A, 2022, , .	3.1	0
1787	Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 560-574.	1.8	3
1788	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2022, 14, 709-725.	2.0	10
1790	Melanoma: An immunotherapy Journey from bench to bedside. Cancer Treatment and Research, 2022, 183, 49-89.	0.5	0

#	ARTICLE	IF	CITATIONS
1791	Role of immune system in TNBC. , 2022, , 121-148.		8
1792	Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. Cancers, 2022, 14, 2181.	3.7	3
1793	Companion Diagnostics: Lessons Learned and the Path Forward From the Programmed Death Ligand-1 Rollout. Archives of Pathology and Laboratory Medicine, 2023, 147, 62-70.	2.5	2
1794	Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression. Cancers, 2022, 14, 2148.	3.7	22
1795	Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations. OncoTargets and Therapy, 2022, Volume 15, 437-468.	2.0	11
1796	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review of Immunology, 2022, 40, 45-74.	21.8	122
1797	The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas. Archives of Gynecology and Obstetrics, 2022, 306, 2133-2142.	1.7	4
1798	Liquid biopsies to occult brain metastasis. Molecular Cancer, 2022, 21, 113.	19.2	23
1799	Cell type identification in spatial transcriptomics data can be improved by leveraging cell-type-informative paired tissue images using a Bayesian probabilistic model. Nucleic Acids Research, 2022, 50, e80-e80.	14.5	6
1800	Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies. Endocrine Reviews, 2022, 43, 1051-1073.	20.1	9
1801	PD-1 mediates decidual $\gamma\delta$ T cells cytotoxicity during recurrent pregnancy loss. American Journal of Reproductive Immunology, 2022, 88, .	1.2	4
1802	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer Immunology Research, 2022, 10, 829-843.	3.4	12
1803	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. Frontiers in Pharmacology, 2022, 13, .	3.5	3
1804	Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape. Medical Oncology, 2022, 39, 92.	2.5	0
1805	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines, 2022, 10, 1181.	3.2	8
1806	The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma. International Journal of Biological Markers, 2022, 37, 322-327.	1.8	5
1807	Programmed Death Ligand 1 (PD-L1) Expression and CD8+ Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy. International Journal of Gynecological Pathology, 0, Publish Ahead of Print, .	1.4	2
1808	Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning. Frontiers in Oncology, 0, 12, .	2.8	2

#	ARTICLE	IF	CITATIONS
1809	Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3071-3085.	4.2	5
1810	The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	3.5	0
1811	KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	3.5	7
1812	PD-L1 expression in 117 sinonasal mucosal melanomas and its association with clinical outcome. <i>Annals of Diagnostic Pathology</i> , 2022, 60, 151976.	1.3	3
1815	Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. <i>International Ophthalmology Clinics</i> , 2022, 62, 49-63.	0.7	6
1816	Whole-genome and transcriptome analysis enhances precision cancer treatment options. <i>Annals of Oncology</i> , 2022, 33, 939-949.	1.2	36
1817	Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome. <i>British Journal of Cancer</i> , 2022, 127, 1162-1171.	6.4	3
1818	The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer. , 2022, 10, e004312.		5
1819	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	21
1820	Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-7.	1.3	2
1821	Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response. <i>Journal of Personalized Medicine</i> , 2022, 12, 958.	2.5	0
1822	Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100603.	1.7	6
1823	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
1824	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	12.8	9
1825	CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Frontiers in Surgery</i> , 0, 9, .	1.4	6
1826	Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 4370-4384.	7.0	15
1827	Association of PD-1/PD-L1 expression and Epstein-â€Barr virus infection in patients with invasive breast cancer. <i>Diagnostic Pathology</i> , 2022, 17, .	2.0	7
1828	The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 169-181.	4.2	9

#	ARTICLE	IF	CITATIONS
1829	Gene-guided OX40L anchoring to tumor cells for synergetic tumor “self-killing” immunotherapy. <i>Bioactive Materials</i> , 2023, 25, 689-700.	15.6	5
1830	Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	1.3	2
1831	Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities. <i>Journal of Clinical Medicine</i> , 2022, 11, 3912.	2.4	14
1832	Analysis and prognostic significance of tumour immune infiltrates and immune microenvironment of m6A-related lncRNAs in patients with gastric cancer. <i>BMC Medical Genomics</i> , 2022, 15, .	1.5	5
1833	A novel risk model based on cuproptosis-related lncRNAs predicted prognosis and indicated immune microenvironment landscape of patients with cutaneous melanoma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	20
1834	Interferon- β predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	1
1835	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
1836	New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. <i>Life</i> , 2022, 12, 1137.	2.4	2
1837	Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1 α -mediated glycolysis in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 4600-4619.	3.3	7
1838	Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces an antitumor immune response to renal cell carcinoma in a murine model. <i>Cell Cycle</i> , 2023, 22, 242-254.	2.6	2
1839	A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, .	12.8	89
1840	PD-L1 testing by immunohistochemistry in Immuno-Oncology. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	1.0	6
1841	Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2022, 8, 1456.	7.1	60
1842	Live Biotherapeutic <i>Lactococcus lactis</i> GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System. <i>Cancers</i> , 2022, 14, 4083.	3.7	7
1843	The epiphany derived from T-cell “inflamed” profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
1844	Systematic “pan-cancer” analysis identifies RBM39 as an immunological and prognostic biomarker. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4859-4871.	3.6	4
1845	Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1380-1391.	6.3	4
1846	Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6

#	ARTICLE	IF	CITATIONS
1847	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	5
1848	A systematic analysis of C5ORF46 in gastrointestinal tumors as a potential prognostic and immunological biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	2
1849	Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 177, 103773.	4.4	18
1850	Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0
1851	A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors. <i>Journal of Controlled Release</i> , 2022, 351, 231-244.	9.9	5
1852	High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities. <i>Cancer Research</i> , 2022, 82, 3917-3931.	0.9	11
1853	Current Trends in Immuno-Oncology. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2023, 21, 96-107.	1.0	1
1854	Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	8
1855	Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
1856	Bench to bedside: research influencing clinical practice in breast cancer. <i>Diagnostic Histopathology</i> , 2022, 28, 473-479.	0.4	2
1857	Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. , 2022, 10, e005052.		9
1858	Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer. <i>Journal of Pharmaceutical Analysis</i> , 2022, 12, 869-878.	5.3	12
1859	Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. , 2022, 10, e005068.		6
1860	Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test. <i>Diagnostic Pathology</i> , 2022, 17, .	2.0	6
1861	The immune landscape of hepatocellular carcinoma—where we are? (Review). <i>Oncology Letters</i> , 2022, 24, .	1.8	6
1862	Dual near-infrared <sc>II</sc> laser modulates the cellular redox state of T cells and augments the efficacy of cancer immunotherapy. <i>FASEB Journal</i> , 2022, 36, .	0.5	3
1863	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9985.	4.1	11
1864	Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. <i>Molecular Oncology</i> , 2023, 17, 792-809.	4.6	8

#	ARTICLE	IF	CITATIONS
1865	Biomarkers and immunotherapy: where are we?. Current Opinion in Oncology, 2022, 34, 579-586.	2.4	6
1866	Editorial: Biomarkers in genitourinary cancers: Volume II. Frontiers in Oncology, 0, 12, .	2.8	0
1867	The DNA damage induced immune response: Implications for cancer therapy. DNA Repair, 2022, 120, 103409.	2.8	6
1868	Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211338.	3.2	1
1869	Development of a Hallmark Pathway-Related Gene Signature Associated with Immune Response for Lower Grade Gliomas. International Journal of Molecular Sciences, 2022, 23, 11971.	4.1	14
1870	Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Nature Communications, 2022, 13, .	12.8	9
1871	Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. BMC Cancer, 2022, 22, .	2.6	4
1873	Identifying tumor immunity-associated molecular features in liver hepatocellular carcinoma by multi-omics analysis. Frontiers in Molecular Biosciences, 0, 9, .	3.5	3
1874	Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination. Frontiers in Immunology, 0, 13, .	4.8	0
1876	Identification of a novel ceRNA network related to prognosis and immunity in HNSCC based on integrated bioinformatic investigation. Scientific Reports, 2022, 12, .	3.3	1
1877	The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. Cancers, 2022, 14, 5144.	3.7	8
1878	Radiomics: A review of current applications and possibilities in the assessment of tumor microenvironment. Diagnostic and Interventional Imaging, 2023, 104, 113-122.	3.2	15
1879	Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile. Biomedicines, 2022, 10, 2732.	3.2	3
1880	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 1003-1014.	4.2	4
1881	The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis. Frontiers in Oncology, 0, 12, .	2.8	5
1882	Advances in immunotherapy for glioblastoma multiforme. Frontiers in Immunology, 0, 13, .	4.8	24
1883	Selection of a <sc>PD</sc>-1 blocking antibody from a novel fully human phage display library. Protein Science, 2022, 31, .	7.6	7
1884	A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer. Frontiers in Oncology, 0, 12, .	2.8	1

#	ARTICLE	IF	CITATIONS
1885	OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5025-5036.	2.5	3
1886	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. International Immunopharmacology, 2022, 113, 109300.	3.8	4
1887	Type I and II interferon signaling in colorectal cancer liver metastasis. Cytokine, 2023, 161, 156075.	3.2	2
1888	Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach. Cancers, 2022, 14, 5605.	3.7	4
1889	Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Scoreâ€‘matching Study. European Urology Open Science, 2022, 46, 88-95.	0.4	2
1890	A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	10
1891	Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy. Cancers, 2022, 14, 5665.	3.7	1
1892	The Tumor Microenvironment in Hepatocellular Carcinoma. , 2022, , 107-137.		0
1893	A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy. Cancer Informatics, 2022, 21, 117693512211360.	1.9	1
1894	Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy. European Medical Journal (Chelmsford, England), 0, , 100-107.	3.0	0
1895	Determination of Interactive States of Immune Checkpoint Regulators in Lung Metastases after Radiofrequency Ablation. Cancers, 2022, 14, 5738.	3.7	0
1896	Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy. Current Oncology, 2022, 29, 8937-8954.	2.2	4
1897	Immunotherapeutic strategies to induce inflection in the immune response: therapy for cancer and COVID-19. Biotechnology and Genetic Engineering Reviews, 0, , 1-40.	6.2	5
1898	Identification of necroptosis-related subtypes, development of a novel signature, and characterization of immune infiltration in colorectal cancer. Frontiers in Immunology, 0, 13, .	4.8	3
1899	Checkpoint inhibitors are a basic scienceâ€‘based, transformative new treatment for lung cancer. Respiriology, 2023, 28, 101-106.	2.3	2
1900	Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates <i>In Vivo</i> Antitumor Activity. Journal of Medicinal Chemistry, 2023, 66, 345-370.	6.4	4
1901	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. International Journal of Molecular Sciences, 2023, 24, 41.	4.1	6
1902	Immunological classification of hepatitis B virus-positive hepatocellular carcinoma by transcriptome analysis. World Journal of Hepatology, 0, 14, 1997-2011.	2.0	0

#	ARTICLE	IF	CITATIONS
1903	Cerebrospinal fluid soluble programmed deathâ€”ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma. British Journal of Haematology, 0, , .	2.5	0
1904	Multi-omics characteristics and immunotherapeutic potential of EZH2 in pan-cancer. Bioscience Reports, 0, , .	2.4	2
1905	The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment. Biomedicines, 2023, 11, 173.	3.2	3
1906	Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation. International Journal of Molecular Sciences, 2023, 24, 1280.	4.1	5
1907	Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8+ T and NK cells. Frontiers in Immunology, 0, 13, .	4.8	13
1908	Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?. Frontiers in Oncology, 0, 12, .	2.8	3
1909	Î³Î² T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature, 2023, 613, 743-750.	27.8	79
1910	Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers. Laboratory Investigation, 2023, 103, 100063.	3.7	9
1911	Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer. Cell Reports, 2023, 42, 111929.	6.4	25
1912	PDJ amplicon in triple negative breast cancer. Scientific Reports, 2023, 13, .	3.3	0
1913	Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. Frontiers in Immunology, 0, 13, .	4.8	1
1914	Unique protein signatures evolve during the course of a delayedâ€”type hypersensitivity reaction in human skin. Journal of Dermatology, 0, , .	1.2	1
1915	An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. Veterinary Sciences, 2023, 10, 19.	1.7	4
1916	Immunogenic Cell Death in Cancer. , 2023, , .		0
1917	Therapeutic cancer vaccination against telomerase: clinical developments in melanoma. Current Opinion in Oncology, 2023, 35, 100-106.	2.4	0
1918	PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells. Journal of Personalized Medicine, 2023, 13, 221.	2.5	8
1920	Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report. Biomedicines, 2023, 11, 311.	3.2	3
1921	Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle. European Medical Journal Oncology, 0, , 70-76.	0.0	1

#	ARTICLE	IF	CITATIONS
1922	Research Current Status and Progress of Immune Checkpoint Inhibitors in the Treat-ment of Non-Small Cell Lung Cancer with Brain Metastases. <i>Advances in Clinical Medicine</i> , 2023, 13, 3638-3642.	0.0	0
1923	Neopeptide load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	1
1926	Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. , 2022, , 1-34.		0
1927	Transcriptome analysis creates a new era of precision medicine for managing recurrent hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 780-799.	3.3	1
1928	Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2023, 2023, 1-12.	1.5	2
1929	Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	0
1931	Cancer immunotherapies: A hope for the incurable?. <i>Frontiers in Molecular Medicine</i> , 0, 3, .	1.9	3
1932	Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report. <i>Case Reports in Oncology</i> , 0, , 81-87.	0.7	0
1934	PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2023, 31, 197-203.	1.2	2
1935	Blocking CD47-SIRPÎ± Signal Axis as Promising Immunotherapy in Ovarian Cancer. <i>Cancer Control</i> , 2023, 30, 107327482311597.	1.8	5
1936	Knockdown of programmed death 1 inhibited progression of papillary thyroid carcinoma in mice. <i>Protein and Peptide Letters</i> , 2023, 30, .	0.9	0
1937	Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1938	Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
1939	Tumor Microenvironment and Its Clinicopathologic and Prognostic Association in Cutaneous and Noncutaneous Angiosarcomas. <i>American Journal of Clinical Pathology</i> , 0, , .	0.7	0
1940	Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 231-241.	3.1	1
1941	Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy. <i>Clinics</i> , 2023, 78, 100177.	1.5	8
1942	Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma. <i>Clinical Oral Investigations</i> , 2023, 27, 1423-1433.	3.0	1
1943	Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. <i>Discover Oncology</i> , 2023, 14, .	2.1	2

#	ARTICLE	IF	CITATIONS
1944	Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment. International Journal of Molecular Sciences, 2023, 24, 6495.	4.1	6
1946	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. Healthcare (Switzerland), 2023, 11, 1073.	2.0	0
1947	Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients. International Journal of Molecular Sciences, 2023, 24, 7114.	4.1	1
1948	Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial. Molecular Therapy, 2023, 31, 2077-2088.	8.2	4
1949	bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer. EBioMedicine, 2023, 91, 104564.	6.1	1
1950	Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era. Cells, 2023, 12, 1049.	4.1	7
1951	High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. , 2023, 11, e006454.		8
1952	Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. , 2023, 11, e006555.		1
1953	Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial. , 2023, 11, e006774.		3
1954	Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity. Expert Review of Anticancer Therapy, 2023, 23, 673-683.	2.4	0
1955	Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine, 2023, 92, 104614.	6.1	7
1956	Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario. Biomedicines, 2023, 11, 1520.	3.2	5
1957	Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination. Cells, 2023, 12, 1504.	4.1	2
1958	The Microbiome in Advanced Melanoma: Where Are We Now?. Current Oncology Reports, 2023, 25, 997-1016.	4.0	2
1959	Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study. European Journal of Cancer, 2023, 190, 112936.	2.8	3
1960	Research progression of PD-1/PD-L1 in non-small cell lung cancer. , 2017, 3, 111-115.		0
1961	The prognostic and predictive roles of plasma C-reactive protein and <sc>PD-L1</sc> in non-small cell lung cancer. Cancer Medicine, 2023, 12, 16087-16097.	2.8	0
1962	PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging. Biochemical and Biophysical Research Communications, 2023, 673, 23-28.	2.1	0

#	ARTICLE	IF	CITATIONS
1963	Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report. Case Reports in Oncology, 0, , 446-452.	0.7	0
1964	Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response. British Journal of Cancer, 2023, 129, 572-585.	6.4	4
1965	A Review of the Flow Cytometric Findings in Classic Hodgkin Lymphoma, Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte-Rich Large B Cell Lymphoma. Clinics in Laboratory Medicine, 2023, , .	1.4	0
1967	Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer. Immunobiology, 2023, 228, 152391.	1.9	2
1968	Insight into immune checkpoint inhibitor therapy for colorectal cancer from the perspective of circadian clocks. Immunology, 0, , .	4.4	0
1969	The clinical relevance and prediction efficacy from therapy of tumor microenvironment related signature score in colorectal cancer. Frontiers in Oncology, 0, 13, .	2.8	0
1970	Whole-Slide Imaging, Mutual Information Registration for Multiplex Immunohistochemistry and Immunofluorescence. Laboratory Investigation, 2023, 103, 100175.	3.7	0
1971	Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1. Acta Pharmacologica Sinica, 0, , .	6.1	0
1972	PD-L1 expression, morphology, and molecular characteristic of a subset of aggressive uterine tumor resembling ovarian sex cord tumor and a literature review. Journal of Ovarian Research, 2023, 16, .	3.0	1
1973	Predictive genomic biomarkers of therapeutic effects in renal cell carcinoma. Cellular Oncology (Dordrecht), 0, , .	4.4	0
1975	Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial. Clinical Cancer Research, 2023, 29, 3026-3036.	7.0	2
1976	Preparation and Bioevaluation of ¹⁸ F-Labeled Small-Molecular Radiotracers <i>via</i> Sulfur(VI) Fluoride Exchange Chemistry for Imaging of Programmed Cell Death Protein Ligand 1 Expression in Tumors. Molecular Pharmaceutics, 2023, 20, 4228-4235.	4.6	4
1977	Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study. European Journal of Medical Research, 2023, 28, .	2.2	3
1978	Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. British Journal of Cancer, 2023, 129, 1212-1224.	6.4	6
1979	Demographic Patterns and Clinicopathological Analysis of Sarcomatoid Renal Cell Carcinoma in US Population. Clinical Genitourinary Cancer, 2024, 22, 38-46.	1.9	0
1980	Prognostic value of $PD\hat{L}1$ and $PD\hat{L}1$ expression in upper tract urothelial carcinoma patients. BJU International, 0, , .	2.5	1
1981	Modulation of $PD\hat{L}1$ expression by standard therapy in head and neck cancer cell lines and exosomes. International Journal of Oncology, 2023, 63, .	3.3	1
1982	A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers, 2023, 15, 3806.	3.7	2

#	ARTICLE	IF	CITATIONS
1983	Metalâ€Free Peroxidaseâ€Mimetic Nanocatalysts for Chemodynamic Vascularâ€Disrupting Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	1
1984	A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades. <i>Cancers</i> , 2023, 15, 4094.	3.7	0
1985	Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 2278-2285.	30.7	12
1986	Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. <i>Nature Communications</i> , 2023, 14, .	12.8	1
1987	Current landscape and challenges ahead of immuno-molecular mechanism and immunotherapy strategy of brain metastases. , 2023, 2, .		0
1989	Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
1990	Immunotherapy: a promising approach for glioma treatment. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	7
1991	Function of Long Noncoding RNAs in Glioma Progression and Treatment Based on the Wnt/ β 2-Catenin and PI3K/AKT Signaling Pathways. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 3929-3942.	3.3	1
1992	C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer. , 2023, 1, .		0
1993	A Chromosome 9p24.1 Amplification in Colorectal Cancer with Metastases to the Kidney and Adrenal Gland: A Case Report. <i>Case Reports in Oncology</i> , 2023, 16, 803-810.	0.7	0
1994	Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	5.0	5
1995	Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15465.	4.1	0
1996	Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis. <i>BioDrugs</i> , 2024, 38, 157-170.	4.6	1
1998	Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2023, 166, 115351.	5.6	1
1999	Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
2000	Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, .	1.9	1
2001	A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, 6, 656-73.	2.1	3
2002	PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes. <i>Cancers</i> , 2023, 15, 4789.	3.7	2

#	ARTICLE	IF	CITATIONS
2003	The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors. <i>Immuno-Oncology Technology</i> , 2023, 20, 100408.	0.3	0
2004	Advances in immunotyping of colorectal cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
2005	Case Report: A management strategy and clinical analysis of primary squamous cell carcinoma of the colon. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
2006	Technological Advancements in Cancer Diagnosis and Prognosis. , 2024, , 1-17.		0
2007	Development and Preclinical Evaluation of [68Ga]BMSH as a New Potent Positron Emission Tomography Tracer for Imaging Programmed Death-Ligand 1 Expression. <i>Pharmaceuticals</i> , 2023, 16, 1487.	3.8	1
2008	An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy. <i>Cancers</i> , 2023, 15, 5084.	3.7	2
2009	Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy”A Systematic Review. <i>Cancers</i> , 2023, 15, 5232.	3.7	1
2010	Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors. <i>Nature Communications</i> , 2023, 14, .	12.8	0
2011	Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	1
2012	Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress. <i>International Immunopharmacology</i> , 2024, 126, 111055.	3.8	2
2013	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. <i>3 Biotech</i> , 2023, 13, .	2.2	0
2014	Joining Forces: The Combined Application of Therapeutic Viruses and Nanomaterials in Cancer Therapy. <i>Molecules</i> , 2023, 28, 7679.	3.8	0
2015	The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1. <i>Japanese Journal of Radiology</i> , 0, , .	2.4	0
2016	Systemic infusion of TLR3-ligand and IFN- γ in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx. , 2023, 11, e007381.		2
2017	Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors. <i>Endocrinology and Metabolism</i> , 0, , .	3.0	0
2018	Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
2020	A T cell receptor β^2 chain- α -directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	0
2021	The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System. <i>Cancers</i> , 2023, 15, 5707.	3.7	0

#	ARTICLE	IF	CITATIONS
2022	Evaluation of Chelator-to-Antibody Ratio on Development of ⁸⁹ Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor. International Journal of Molecular Sciences, 2023, 24, 17132.	4.1	1
2023	EPRIM: An approach of identifying cancer immune-related epigenetic regulators. Molecular Therapy - Nucleic Acids, 2024, 35, 102100.	5.1	0
2024	Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma. Cytotherapy, 2024, 26, 242-251.	0.7	0
2025	Development, Characterization, and Radiation Dosimetry Studies of ¹⁸ F-BMS-986229, a ¹⁸ F-Labeled PD-L1 Macrocytic Peptide PET Tracer. Molecular Imaging and Biology, 0, , .	2.6	2
2026	Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review. Cancer Cell International, 2024, 24, .	4.1	0
2027	LC-MS bioanalysis of protein biomarkers and protein therapeutics in formalin-fixed paraffin-embedded tissue specimens. Bioanalysis, 2024, 16, 245-258.	1.5	0
2028	Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics. European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51, 1582-1592.	6.4	2
2029	High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Therapeutic Advances in Medical Oncology, 2024, 16, .	3.2	0
2031	Effective extracellular vesicles in glioma: Focusing on effective ncRNA exosomes and immunotherapy methods for treatment. Cell Biochemistry and Function, 2024, 42, .	2.9	0
2032	Mapping the single cell spatial immune landscapes of the melanoma microenvironment. Clinical and Experimental Metastasis, 0, , .	3.3	0
2033	Role of stromal PD-L1 expression in colorectal liver metastasis. BMC Cancer, 2024, 24, .	2.6	0
2034	Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach. Biomedicines, 2024, 12, 217.	3.2	0
2035	Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma. Cancers, 2024, 16, 435.	3.7	0
2036	Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review. Cancers, 2024, 16, 523.	3.7	0
2037	PLAU and GREM1 are prognostic biomarkers for predicting immune response in lung adenocarcinoma. Medicine (United States), 2024, 103, e37041.	1.0	0
2038	Remarkable response to pazopanib plus vivolumab in a patient with pericardial synovial sarcoma carrying a novel genotype <sc>BRCA2</sc> c.<sc>968dupT: A case report</sc>. Thoracic Cancer, 2024, 15, 667-671.	1.9	0
2040	Expression patterns of E2Fs identify tumor microenvironment features in human gastric cancer. PeerJ, 0, 12, e16911.	2.0	0
2041	Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection. Journal of Neuro-Oncology, 2024, 167, 155-167.	2.9	0

#	ARTICLE	IF	CITATIONS
2042	An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β ² with enhanced antitumor efficacies. International Immunopharmacology, 2024, 130, 111698.	3.8	0
2043	The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC). Cells, 2024, 13, 413.	4.1	0
2044	Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?. Current Opinion in Oncology, 2024, 36, 63-68.	2.4	0
2045	Oxaliplatin lipidated prodrug synergistically enhances the anti-colorectal cancer effect of IL12 mRNA. Drug Delivery and Translational Research, 0, , .	5.8	0
2046	The role of artificial intelligence in radiology and interventional oncology. , 2024, , 193-200.		0
2047	Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. Journal of Pathology, 0, , .	4.5	0
2048	Prognostic and predictive role of immune microenvironment in colorectal cancer. World Journal of Gastrointestinal Oncology, 0, 16, 643-652.	2.0	0
2049	Density of high endothelial venules and PDL-1 expression: relationship with tumor-infiltrating lymphocytes in primary cutaneous melanomas. Anais Da Academia Brasileira De Ciencias, 2024, 96, .	0.8	0
2050	Targeted Ultrasound Nanobubbles Therapy for Prostate Cancer via Immuno-Sonodynamic Effect. International Journal of Nanomedicine, 0, Volume 19, 2793-2806.	6.7	0